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Mechanism of yeast prion protein aggregation and strain formation 
By 
Tejas Baba Chandrashekar Kalastavadi 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Molecular Genetics and Genomics) 
Washington University in Saint Louis, 2010 
Professor Heather L. True, Chairperson 
 
Misfolding and aggregation of the prion protein (PrP) causes fatal 
neurodegenerative diseases in many mammalian species, including humans.  Mutations in 
the gene encoding PrP are associated with ~15% of the incidences, while, the vast 
majority of the cases are sporadic.  Interestingly, prion diseases also display pathological 
variation, suggesting that there are multiple different strains.  
To elucidate the mechanism of prion protein aggregation and strain formation, I 
have taken advantage of the yeast prions [PSI+] and [RNQ+] and their protein 
determinants Sup35p and Rnq1p, respectively.  Using a Sup35-PrP chimera, I have 
investigated the effect of the disease associated oligopeptide repeat domain (ORD) 
expansions of PrP, on prion propagation and amyloid fiber formation.  We previously 
determined that these chimeric proteins maintain the [PSI+] yeast prion phenotype.  
Interestingly, we noted that the repeat expanded chimeric prions maintained a stronger 
strain of [PSI+]. Investigations of the chimeric proteins in vitro revealed that repeat-
expansions also increase aggregation propensity.  However, despite the increased 
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aggregation propensity of the repeat expanded proteins, there was no corresponding 
increase in the stability of the fibers.  Therefore, we predicted that the repeat expansions 
may spontaneously convert to [PRION+] with a much higher frequency.  Contrary to our 
prediction, we observed that enhanced conversion of the repeat expanded chimeras only 
occurred in the presence of another prion, [RNQ+] prion.  
The [RNQ+] prion has previously been implicated in the de novo induction of the 
[PSI+] prion, and therefore also is referred to as [PIN+] for PSI Inducible.  However, the 
interaction of [PSI+] and [RNQ+] prions has not been clearly defined and the physical 
basis for the strains of [RNQ+] has been largely unexplored.  I have, for the first time, 
been able to create different strains of [RNQ+] in vitro.  Rnq1p prion forming domain 
(Rnq1p PFD) can form fibers that template the conversion of monomeric protein into 
amyloid fibers.  Further, Rnq1p PFD has a shorter lag phase for fiber formation at 37○C 
when compared to 25○C.  Surprisingly, increasing the temperature at which fibers are 
formed also increased the stability of these fibers.  Additionally, the morphology of the 
fibers is dramatically altered at different temperatures.  These distinct biochemical 
properties manifest as different distributions of [RNQ+] strains when the fibers are 
transformed into yeast cells.  Transformants of Rnq1p PFD fibers resulted in weak, 
medium and strong [RNQ+] strains.  The amount of aggregated protein and the ability to 
propagate the prion increased with the strength of the prion strain.  However, the [PIN+] 
prion phenotype did not correlate with the [RNQ+] prion strength.  The weak and strong 
[RNQ+] both induced the [PSI+] prion with equally higher efficiencies when compared to 
the medium [RNQ+].  Coincidently, the weak [RNQ+] strain has very similar properties 
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to the previously identified very high [PIN+] strain suggesting an incongruent 
relationship between [RNQ+] and [PIN+] associated phenotypes.   
Determining the biochemical properties of the Rnq1p PFD fibers and their ability 
to induce specific distributions of prion strains has enabled us to dissect the mechanism 
for the [RNQ+] prion strains.  Additionally, I have been able to distinguish the 
mechanisms involved in determining the [PIN+] prion strains from the [RNQ+] strains.  
Incorporating the mechanism of strain formation elucidated by investigating [RNQ+] 
strains, with the previously proposed model for [PSI+] strains, has provided us a 
framework to understand both general and specific properties of prion disease strains. 
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Chapter 1: Background and Significance 
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1.1 Overview: Protein misfolding and aggregation-based diseases 
A vast number of diseases in humans have been linked to misfolding and 
aggregation of a functionally and sequentially diverse set of endogenously expressed 
proteins (Table 1.1) (1).  Many fatal neurodegenerative disorders are part of this class of 
protein misfolding diseases (2).  The cause for misfolding and aggregation of these 
proteins is not clearly understood in most cases and as such, the onset of disease is 
considered to be sporadic (1).  A subset of these diseases is linked to specific mutations 
in the gene encoding the protein that is aggregated.  An interesting feature of these 
proteins is that they do not form non-specific amorphous aggregates but instead self-
assemble into ordered amyloid fibers (2).  The consequence that most of these mutations 
have on protein misfolding, conformational conversion and eventual aggregation 
(amyloid formation) is not clearly defined, however.  
The original introduction of the term “amyloid” and description for macroscopic 
deposits in human tissue was provided by Virchow in 1854 (3).  It was later determined 
that these inclusions were proteinaceous in nature and associated with various clinical 
symptoms (3).  Major advancements since then have provided clues toward 
understanding the mechanisms by which they are formed and the role they play in 
physiology and pathology of various organisms from bacteria to humans (1).  Many 
important questions remain, however, including the effect that disease-associated 
mutations have on amyloid fiber formation and disease onset, physical basis and 
consequence of conformational diversity of amyloid fibers, and properties that bestow 
certain amyloid-like aggregates to be infectious.   
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Table 1.1 Human diseases associated with amyloid deposition 
Disease Name Fibril protein/ peptide 
Prion disease (CJD, GSS, FFI, Kuru) Prion Protein 
Alzheimer’s disease (AD) Amyloid β (Aβ) 
Parkinson’s disease (PD) α-synuclein 
Frontotemporal lobar dementia (FLTD) Tau and TDP-43 
Amyotrophic lateral sclerosis (ALS) Superoxide dismutase (SOD), TDP-43 
Huntington disease (HD) Huntingtin exon-1 with polyQ expansion 
Spinocerebellar ataxias (SCAs) Ataxins with polyQ expansion 
Senile systemic amyloidosis Transthyretin 
Reactive systemic AA amyloidosis Serum amyloid A protein 
Haemodialysis amyloidosis β2microglobulin 
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Table 1.2 Saccharomyces cerevisiae prion proteins  
Prion Protein determinant Function of protein (modified from (4)) 
[URE3] Ure2p Nitrogen catabolism  
[PSI+] Sup35p Translation termination 
[RNQ+] Rnq1p Unknown function, promotes induction of [PSI+] 
[SWI+] Swi1p Transcriptional regulation 
[MCA] Mca1p Regulation of apoptosis 
[OCT+] Cyc8p Transcriptional repression 
[MOT3+] Mot3p Transcriptional regulation 
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The most common protein-aggregation based neurodegenerative diseases are 
Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) (2).  The onset of these diseases 
is very strongly age dependent, which may be a consequence of a decreased functionality 
of the quality control machinery.   Diseases caused by expansion of a poly-glutamine 
tract in the protein, such as Huntington’s disease, show a strong inverse correlation 
between the age of onset and the length of the poly-glutamine expansion (5).  This may 
be due to an increase in the intrinsic ability of the mutant proteins to aggregate and cause 
disease.  Although, neurodegenerative diseases tend to show strong age-dependence, 
there is considerable variation in clinical and pathological manifestation of several human 
amyloid disorders including prion disease (6).  Self-propagating variation in the 
conformation of the aggregated amyloid fibers has been proposed to be the molecular 
basis for this phenotypic variation (7).  
Various models have been suggested to explain the effect of protein aggregates on 
cellular function that results in disease. Both loss-of-function of the aggregated protein as 
well as toxic gain-of-function of the aggregates have been considered for some diseases. 
Interestingly, some evidence suggests that it is actually on-pathway oligomers that are 
toxic to cells and that the amyloid fibers may provide a protective effect by sequestering 
the oligomers (8,9).  Deciphering the structural information of amyloid fibers has been 
fairly successful.  In comparison elucidating the structure of the transient oligomers has 
been quite challenging, although, recent biophysical experiments show promising results 
(10).  
Intriguingly, not all protein aggregates are disease-causing.  Some amyloid-like 
aggregates of proteins are thought to have functional roles (1).  In the yeast, 
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Saccharomyces cerevisiae, many different protein aggregates have been proposed to have 
roles in cellular physiology and adaptation (Table 1.2) (4).  Investigation of these yeast 
proteins and their properties has provided important insights into the mechanisms of 
protein aggregation.  
In this chapter, I will focus on protein misfolding and the ability of proteins to 
form amyloid fibers.  Subsequently, I will discuss prion diseases specifically and features 
of the prion protein that are unlike other protein misfolding disorders.  I will place special 
emphasis on two topics 1) specific class of inherited prion disease, and 2) the 
phenomenon of prion strains and the ability of certain proteins to be infectious in nature.  
Finally, I will discuss work done in yeast using endogenous prion proteins to understand 
various aspects of protein misfolding disorders and specifically with respect to prion 
disease.    
 
1.2 Protein misfolding and amyloid fiber formation 
 Proper folding of proteins is critical for cellular function and physiology and the 
cell has developed many mechanisms to deal with misfolded proteins (11).  The problem 
of how proteins fold into their native structure has been a long-standing question.  In 
1973 Christian Anfinsen and colleagues postulated that the native structure of a protein is 
the thermodynamically stable structure and that it only depends on the amino acid 
sequence and conditions of the solution (12).  More recently, Dobson and colleagues 
have provided evidence to suggest that most polypeptide chains, irrespective of the 
specific amino acid sequence, have the ability to form amyloid fibers given the 
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appropriate solution conditions (13).  However, the propensity and the ability of a 
specific protein to form fibers in vivo is dependens on the amino-acid sequence (14).  
 Various models have been proposed to explain the formation of amyloid fibers 
from otherwise folded proteins (illustrated in Figure 3) (1).  Proteins that are normally in 
their native conformation, through an as yet unknown mechanism, form predominantly β-
sheet rich amyloid fibers.  It has yet to be determined whether the monomeric, natively-
folded protein undergoes a conformational change prior to oligomerizing and forming 
amyloid fibers, or if the monomers oligomerize initially and then acquire a different 
conformation.  It is possible that both these pathways are utilized, but the specific 
pathway that a protein takes toward forming fibers is dependent on the specific properties 
of the polypeptide in question.  In addition, certain mutations associated with protein 
aggregation diseases have been shown to destabilize the native conformation of the 
protein and thereby promote aggregation, at least in vitro (15,16).  
 Although the precise timing of the conformational change that occurs in the 
proteins that form amyloid fibers is not known, it has been well-established that amyloid 
formation occurs through a nucleation-dependent pathway (1).  The time course for fiber 
formation as assayed by Thioflavin-T (Th-T), typically follows a sigmoidal growth curve 
consisting of a lag phase, followed by an exponential growth phase, and finally a plateau 
phase that indicates the end of the reaction (17,18).  The lag phase is considered to be the 
rate-limiting step during which the nucleus is formed.  The lag phase can be eliminated 
by adding preformed fibers to a reaction containing monomeric protein, thereby 
nucleating or seeding the reaction (1).  Very little is known about the changes that may be  
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Figure 1 Model for protein aggregation pathways (from Chiti and Dobson, Annu. Rev. 
Biochem. 2006. 75:333-66) 
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 occurring during the lag phase and this has proven to be a very interesting and 
challenging area of research.  
 The amyloid fibers formed in vitro by the various polypeptides and proteins have 
a common set of characteristics.  They can be imaged using either transmission electron 
microscopy (TEM) or atomic force microscopy (AFM). The amyloid fibers are ~10 nm in 
diameter and can assemble with other fibers to form higher-order structures (19).  X-ray  
diffraction experiments have shown that individual protofibrils are composed of 
assembled monomeric proteins or peptides such that the polypeptide chain forms β-
strands that run perpendicular to the axis of the fibril (Figure 1A and 1B) (20).  The fibers 
can bind dyes such as thioflavin-T (ThT) and Congo Red (CR) (21).  Recent attempts to 
solve the structure of amyloid fibers have been successful.  The use of solid-state NMR 
(SSNMR) and X-ray crystal diffraction analysis of nano- and microcrystals using peptide 
fragments from amyloidogenic proteins have proven useful in defining the structural 
details of the fibers (22-25).  A peptide (GNNQQNY) derived from Sup35p, a yeast prion 
protein, formed three-dimensional crystals that possessed the characteristics of amyloid 
fibers (25).  For this specific peptide, each individual peptide molecule formed a single β-
strand and stacked in-parallel and in-register to form a single β-sheet (Figure 1C and 1D). 
The β-sheets are also packed in pairs in parallel to each other (25).  Since the discovery of 
the amyloid structure of the Sup35p derived peptide, other peptides obtained from the 
sequence of a milieu of proteins have shown a range of atomic architectures for amyloid 
fibers (26).  These diverse structures provide a plausible molecular explanation for the 
existence of the strain phenomena in amyloid-related disorders.    
 9
    
Figure 2 Structure of amyloid fibril (from Baxa, U. Curr Alzheimer Res. 2008 June; 5(3): 
308-318) 
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 In contrast to the progress made towards unraveling the structure of the amyloid 
fiber, there is little known about what may prove to be the most interesting of species in 
the pathway of amyloid formation, the oligomers that act as the intermediates between 
monomers and fibers.  There is growing evidence to suggest that such oligomers are the 
toxic species that result in cell death and cause disease (9).  The discovery of an antibody 
that specifically recognizes oligomers and does so with oligomers formed from multiple 
proteins suggested common structural characteristics of these species (27).  However, 
there is data suggesting the existence of low molecular weight oligomers that are 
relatively disorganized prior to the formation of a structure that can be recognized by the 
oligomer specific antibodies (28).  Considering the information currently available, one 
can imagine many different pathways a protein can take to go from natively-folded 
protein to amyloid fibers that constitute protein deposits associated with various diseases.   
 
1.3 Repeat expansion proteins and neurodegenerative disease 
 Expansion of the CAG codon that encodes the amino acid glutamine has been 
associated with various neurodegenerative diseases (29).  These so called 
“polyglutamine” diseases, due to the nature of the expanded glutamine tract, include 
Huntington disease (HD), several spinocerebellar ataxias (SCAs) and spinal bulbar 
muscular atrophy (SBMA) (29).  Large inclusions of the proteins with the expanded 
glutamine tract have been associated with disease and were thought to be the cause of 
neurodegeneration (30).  However, there is evidence to suggest that these aggregated 
protein inclusions may not be obligatorily associated with disease (31).  Cases of disease 
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in the absence of protein aggregates, as well as the absence of any disease pathology in 
the presence of aggregates have been observed (32,33).   
Expanded polyglutamine proteins have an increased propensity to aggregate and 
form ordered amyloid fibers in vitro (34).  Additionally, the poly-Q length seems to play 
a critical role in aggregation potential and toxicity (35).  There is a strong inverse 
correlation between age of onset of disease and length of poly-Q expansion (36).  Loss-
of-function, toxic gain-of-function, or altered function have been attributed as 
mechanisms that can result in the onset of the growing number of repeat expansion 
related neurodegenerative diseases (30).  Although the poly-Q expansion has been the 
main focus of research and has bared the brunt of blame for disease, it is becoming 
increasing clear that sequence around the poly-Q expansion is a crucial determinant in 
pathogenesis (37).  
In the case of prion disease, insertion mutations that expand an octapeptide repeat 
domain (ORD) from the endogenous number of five repeats to and additional two to nine 
repeats causes a dominantally inherited form of prion disease in humans (38).  Significant 
effort has been placed on understanding the effect of the poly-Q insertion mutations on 
protein folding and aggregation, however, not much is known about the effect of the 
ORD expansion mutations on protein folding with the prion protein.  In chapter two, I 
discuss work done to address this question and provide a plausible biochemical 
explanation for the onset of disease due to expansion in the ORD in PrP.   
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1.4 Prion proteins and disease 
 Transmissible spongiform encephalopathies (TSEs or prion diseases) have been 
one of the most intriguing and enigmatic diseases.  This disease first presented itself as 
Kuru among the Fore tribe in Papua New Guinea and was studied extensively by D. 
Carleton Gajdusek (39).  It was initially thought to be caused by a slow viral infection 
with long incubation times and progressive pathology that ended in fatality (40).  
Subsequently, many other neurodegenerative diseases similar to Kuru, such as scrapie in 
sheep and Creutzfeldt-Jakob disease in humans (CJD) were grouped together based on 
their similarities (41).  More interestingly, both scrapie and CJD were also shown to be 
transmissible (42,43). 
 Human prion disease presents itself as many different disorders.  As mentioned 
earlier, Kuru and CJD are two types of prion disease.  Gerstmann-Straussler syndrome 
(GSS), variant CJD (vCJD) and Fatal Familial Insomnia (FFI) are also disorders that are 
referred to as prion diseases (44).  Prion disease itself may have genetic, infectious or 
sporadic origins but all cases present with spongiform degeneration.   
Based on various lines of evidence Stanley Prusiner proposed that the transmissible agent 
in these diseases was not a virus, but a small proteinaceous infectious particle he termed 
“prion” (45).  He noted that the infectious agent was protease sensitive, but agents that 
modified nucleic acids failed to cause inactivation.  It was later shown that prion particles 
are primarily composed of an abnormal conformation of the prion protein (PrP), a ~27 
kDa protein encoded by the PRNP gene, endogenously expressed in mammalian cells 
(46).  PrP is a membrane-anchored protein that undergoes cleavage of its signal peptide 
and glycosylation at two different sites (47).  It is processed through the  
 13
  
 
Figure 3 Disease associated mutations in PrP (from van der Kamp, M. W. et al. Protein 
Engineering, Design and Selection 2009 22:461-468) 
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secretory pathway and anchored to the cell surface via the GPI anchor.  Although the 
ultimate proof for prion diseases to be propagated solely by misfolded protein is still 
incomplete, there is growing evidence to suggest that this model infact is accurate (48). 
 At least 30 mutations of the PRNP gene (Figure 2) are now known to cause 
inherited forms of human prion diseases (47).  Approximately 10-15% of the incidence of 
prion disease can be accounted for by the presence of inherited mutation (49).  Although 
the biological function of PrP has not yet been determined, mutations in this gene 
presumably influence the stability, processing and/or cellular interactions of the protein to 
cause disease (50).  There is evidence to suggest that there are different ways that 
different mutations effect PrP, however, and many questions remain about the 
mechanisms by which many mutations cause disease.  In the second chapter of my thesis 
I will specifically discuss work I did to elucidate the mechanism by which one class of 
mutations in PrP, repeat expansions, affects amyloid fiber formation and stability. 
 In a manner similar to other protein misfolding amyloid based diseases, PrP can 
undergo a conformational change from its native, globular state to an aggregated,-
structurally distinct form (51).  During this conformational change PrPc (cellular) which 
is sensitive to protease treatment shifts from having some α-helical structure to one that is 
predominantly β-sheet rich and resistant to protease treatment, called PrPSc (Scrapie) 
(40,50,52).  Several mutations associated with prion disease significantly destabilize the 
PrPc conformer that may then proceed to form PrPSc (53).  The converted PrPSc is 
believed to propagate by binding to PrPc and acting template for PrPc to refold into the 
abnormal isoform.  The development of the protein misfolding cyclic amplification assay 
(PMCA) has provided substantial evidence to suggest a templated conversion model (54).  
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The specific mechanisms that the protein follows to convert from a natively folded 
structure to an abnormal structure, and subsequently convert native protein to join the 
aggregate, are still a mystery.  Recombinant full-length PrP can be induced to form 
amyloid fibers in vitro under various conditions (51).  However, these fibers formed from 
recombinant PrP does not lead to an infectious PrPSc conformation unless it is in the 
presence of lipids or RNA (48).   
The PrP protein contains an octapeptide repeat domain (ORD) in the N-terminal 
region of the protein between amino acids 51 and 91 (47).  In the wild type protein, there 
are five repeats in the ORD (49).  Insertion of more than two additional octapeptide 
repeats in this region causes inherited prion disease (49).  Considerable variability in 
clinical phenotype has been reported for this group of mutations, with age of onset 
ranging from 21-82 years of age and duration of disease ranging from 3 months to 21 
years (49).  In addition, pathological features of families that have been reported to have 
ORD expansions have been highly variable.  Despite this variability, it has been shown 
by Croes and colleagues that there is a negative correlation, albeit a weak one, between 
age of onset and duration of disease with size of the insertion in the ORD (55).  In 
chapter two of this thesis, I discuss in detail work done to elucidate the effect that ORD 
expansions that result in a total of eight, 11, and 14 repeats have on amyloid fiber 
formation and stability.   
The diversity in clinical symptoms and pathology of prion disease that arise either 
just from the wild type protein or within families harboring the same mutant provides a 
basis for the significance and existence of multiple prion “strains” (40,50,56).  Various 
experiments have shown that when different prion strains are injected to identical hosts, 
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they develop distinct prion-disease phenotypes (57).  Traits that have been used to 
classify prion strains include aggregate deposition, incubation times, tissue pathology and 
cellular targets (44). There is growing evidence to suggest that specificity of strains arises 
from conformational changes in the aggregated protein and that the strains are defined by 
the tertiary or supramolecular structure of the prion particle.   
 
1.5 Infectious and non-infectious amyloids 
 The nucleated conformation conversion model for amyloid fiber formation 
previously described may be a common feature for all amyloidogenic proteins (17,18).  
As mentioned earlier, amyloidogenesis of many proteins leads to protein misfolding 
disorders (1).  In fact, the similarity is quite uncanny, in that, the features of the fibers 
such as β-sheet content, dye-binding and protease resistance are all shared (58).  The 
ability of preformed seeds to template the conformational change of previously 
unconverted monomer and form amyloid fibers is analogous to the propagation of prions 
(19).   
 Recent studies have shown that, in cell culture, poly-Q aggregates and tau 
aggregates can be internalized by cells (59,60).  Thus, tt is theoretically possible that the 
internalized aggregates can convert soluble cytoplasmic proteins and stimulate 
aggregation.  It is conceivable that all protein misfolding disorders have the potential to 
be “infectious”, however, other than PrPSc, none of the other protein misfolding disorders 
have had detectable naturally-occuring infectivity and none have given rise to disease 
epidemics such as Kuru and BSE.   
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 The closest any other disease has come to being “prion-like” is AA amyloidosis.  
In mammals that have AA amyloidosis, the N-terminal-derived serum amyloid A (SAA) 
is accumulated in multiple organs such as the spleen and liver when the levels of blood 
SAA are chronically elevated (44).  The “infectivity” of AA amyloidosis may explain the 
high prevalence of this disease in captive cheetahs (61).  AA amyloidosis and 
Alzheimer’s disease (AD) have both been shown to be infectious in laboratory animals as 
long as the recipient animals have elevated levels of SAA or Aβ (44,62).  
 Although the role of protein misfolding and amyloid fiber formation has been 
unequivocally implicated in many diseases, it remains to be seen as to how many of them 
have a prion-like mechanism of disease transmission.  More importantly, understanding 
what differences distinguish protein aggregates that are infectious versus others that are 
not is very intriguing.  Chapter four of this thesis discusses a model I have developed that 
provides a means of addressing this question from a structural as well as a biochemical 
perspective.      
 
1.6 Yeast prions  
 Although only one prion protein, PrP, has been identified in mammals, many 
different proteins in the yeast Saccharomyces cerevisiae have been shown to have prion-
like properties (Table 2) (4).  In yeast however, prion proteins do not cause disease, but 
act as epigenetic elements of heredity (63).  They may play a role in modifying 
phenotypes in a manner that allows the yeast adapt to changing environmental conditions 
(64,65).   
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 The [PSI+] factor was initially identified in 1965 (66), it was not until almost 
another 30 years later that Reed Wickner suggested that [PSI] and [URE3], another yeast 
cytoplasmic factor, were in fact prions (67).  He proposed four criteria that need to be 
fulfilled for prion-based phenotypic properties.  First, the phenotype should be inherited 
cytoplasmically suggesting that the determinant is not a genetic mutation.  Second, the 
prion state was dependent on the expression of the protein determinant.  Third, mutations 
in the genetic determinant of the prion displayed the prion phenotype.  Fourth, the genetic 
mutation was recessive; however, the prion state was dominant (66).   
The [PSI+] prion is one of the most well -characterized prions in yeast (68).  It is 
encoded by the Sup35p, the eukaryotic release factor 3 (eRF3) in yeast and is an essential 
protein that functions in translation termination (69-71).  It was initially identified in a 
genetic screen as a mutant that enhanced suppression of stop codons by SUP16 (SUQ5) 
(72).  One can assay for the prion state of a cell by the suppression of the nonsense allele 
ade1-14.  In the [psi-] state, Sup35p is in its normal soluble form and there is no nonsense 
suppression of the ade1-14 allele resulting in the accumulation of a red pigment in the 
colonies.  In the [PSI+] state, Sup35p is aggregated and non-functional, allowing for 
nonsense suppression (73,74).  This provides for expression of full length Ade1p, 
resulting in a complete adenine biosynthetic pathway and the colonies are white.  
The Sup35p can be divided into three domains: the N-terminal domain (N), amino 
acids 1-123, the middle domain (M), amino acids 124-253, and the carboxy-terminal 
domain (C), amino acids 254-685 (68). The NM region is dispensable for viability, but 
the N domain is necessary and sufficient for [PSI+] propagation (75-77).  The C-terminal 
domain is essential for viability and is necessary for the translation termination function 
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of the protein (75,78).  The N domain of Sup35p can be further dissected into the QN-
rich domain, amino acids 1-40 and the oligopeptide repeat domain (ORD), amino acids 
41-97 (66,79,80).  Mutations of polar residues in the QN-rich domain can have profound 
effects on [PSI+] propagation including loss of the prion state, forming of “cryptic” 
[PSI+] and “Psi no more” (PNM) forms (81,82).  The ORD contains five copies and one 
incomplete copy of an oligopeptide.  The number of repeats within the ORD is very 
important and the loss of even a single repeat results in the loss of the prion (76,83,84).  
In contrast, increasing the number of repeats by the addition of two repeats increases the 
rate of spontaneous conversion of [psi-] cells to [PSI+] (83).   
The prion domain of Sup35p has been shown to form amyloid fibers in vitro 
(85,86).  In addition a nucleated polymerization model has been suggested based on the 
ability of preformed “seeds” to enhance the formation of these amyloid fibers (18,85,86).  
Lysates obtained from [PSI+] cells, but not [psi-] cells, are also capable of seeding 
amyloid fiber formation (85).  Fibers formed from recombinant of Sup35NM protein 
when introduced into [psi-] cells convert and acquire the [PSI+] phenotype, providing 
conclusive evidence that Sup35p amyloid fibers are in fact bona fide infectious particles 
(87,88).   
 Sup35p fractionates to the pellet fraction when lysates from [PSI+] cells are 
subjected to high speed centrifugation because it is present as high molecular weight 
aggregates in these cells.  In [psi-] cells, Sup35p is soluble and therefore does not pellet 
and is present in the soluble fraction (73,74).  Additionally, the NM domain of Sup35 
when fused to GFP mediates the aggregation of GFP into punctuate foci specifically in 
[PSI+] cells and displays a diffuse patter in in [psi-] cells (73).   
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The structural analysis of Sup35NM amyloid fibers has proven to be extremely 
challenging and the proposed structures are a hotly debated topic in the field.  The two 
proposed structures suggest either an in-register parallel β-sheet or a β-helix (89).  So far 
techniques including fluorescence labeling, solid-state NMR and (H/D) exchange NMR 
have been used to probe the structure of Sup35NM amyloid fibers (90-92).  There is 
compelling evidence for both structures, and additional work is needed to identify the 
biologically relevant structure.  
Interestingly, the repeats from Sup35p (consensus: PQGGYQQYN) bear a 
striking resemblance to the oligopeptide repeats present in PrP (consensus: 
PHGGGWGQ) (93).  In our lab, we previously assayed the affect of the wild type ORD 
from PrP as well as repeat expansions of the ORD associated with prion disease on 
[PSI+] prion state in vivo (94).  In chapter 2 of this thesis, I discuss the effect that the 
wild type as well as disease-associated ORDs of PrP had within the context of Sup35NM 
amyloid fiber formation in vitro. 
 
1.7 Yeast prion strains  
Analogous to the perplexing property of mammalian prions being able to exist as 
different “strains” of PrPSc, a subset of yeast prions including [PSI+] can maintain and 
propagate distinct strains, although yeast strains are generally referred to as “variants”, 
since the term “strain” is used to distinguish different genetic backgrounds (40,66).  
The hypothesis that a protein can aggregate and form a number of different 
ordered, self-propagating conformational states is very exciting.  There is growing 
evidence, especially from the yeast prion field, to suggest that this is in fact the case.  In 
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chapter 3 of this thesis I discuss work done to provide a framework on which to base a 
universal physical basis for the formation of prion strains based on the yeast prion 
[RNQ+].   
Extensive work done with Sup35p and variants of [PSI+] has provided a wealth of 
information towards understanding the molecular mechanisms of prion variant formation.  
Amyloid fibers of Sup35NM with different physical properties can be transformed into 
yeast to induce distinct [PSI+] phenotypes (88,95).  The physical properties of Sup35NM 
fibers can be simply influenced by changing the temperature at which the fibers are 
formed.  The thermostability of the fibers formed at different temperatures is distinct.  
For example, Sup35NM fibers formed at 4○C have a lower melting point than those 
formed at 25○C, suggesting that there are gross structural differences between them.  
Additionally, when 4○C fibers were transformed into [psi-] yeast, they gave primarily 
strong [PSI+] variants and 25○C fibers transformed gave weak [PSI+] variants (88).   
Several studies using multiple techniques have been conducted to identify 
structural differences of fibers formed at different temperatures (90,91).  Cysteine mutant 
studies using fluorescent dyes identified differences in the length of the amyloid core, i.e. 
the amino acids in the protein that are buried and protected from the solvent, and the 
amino acids involved in forming either inter- or intra-molecular contacts necessary for 
amyloid fiber formation.  Fibers formed at 4○C had a smaller amyloid core (amino acids 
31-86) and 25○C fibers had a longer core (amino acides 21-121).  The amyloid core as 
determined by another technique, H/D exchange NMR, suggested that 4○C fibers have a 
core spanning amino acids 4-40 and 37○C fibers have a core spanning amino acids 4-70. 
Although the H/D exchange NMR results do not agree with the fluorescence assay based 
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results quantitatively, i.e. the specific amino acid positions, both techniques agree with 
each other qualitatively, i.e. the length of the amyloid core changes and a shorter core 
yields stronger [PSI+] variants.  The thermostabilities of the fibers are consistent with the 
length of the amyloid core of the fibers formed at the different temperatures.  The 
amyloid fiber with longer cores are more stable than the fibers with weaker cores 
(88,89,96).  It is reasonable to speculate that fibers that are stronger in vitro produce 
weaker prion pheotypes in vivo because the aggregates in this conformation are harder to 
break apart and therefore have fewer ends (or contacts) to template conversion of soluble 
protein.  Consequently, weaker fibers may be easier to fragment, providing more ends for 
templating and subsequent propagation to daughter cells.  Furthermore, specific inter-
molecular contacts have been shown to be responsible for certain prion variants (90).  
Although differences in variants of [PSI+] have relatively large structural changes, recent 
crystallographic studies with amyloid forming peptides suggest that subtle changes may 
be sufficient for prion variant formation (26).   
In chapter three of this thesis, we discuss pioneering work done toward 
understanding biochemical and structural properties of another prion [RNQ+].  We hope 
this and future studies will help illustrate universalities amongst prion strain nucleation 
and propagation.  
[RNQ+]/ [PIN+] prion  The [PIN+] prion was initially identified as a non-
Mendelian trait of S. cerevisiae that is required for efficient [PSI+] induction when 
Sup35p is overexpressed (97,98).  Many different proteins were identified as potential 
factors that when overexpressed made yeast cells [PIN+] (99).  However, the most 
commonly found [PIN+] element in strains of yeast is that propagated by Rnq1p.  As 
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such, in most cases, [PIN+] and [RNQ+] are used synonymously and refer to the prion 
state of the Rnq1p. Rnq1p does not have a known biological function in its globular or 
soluble state, however, the [RNQ+] prion influences the induction of [PSI+].  
Interestingly, Rnq1p was independently identified as a prion because it contained a 
glutamine (Q) and asparagine (A) rich domain (similar to prion forming domains of 
Sup35p and Ure2p) (100).  The prion state of Rnq1p is represented as [RNQ+] and the 
non-prion state is [rnq-] (100).   
Rnq1p is a 42.5 kDa protein that can be divided into primarily two domains: 
amino acids 1-152 constitute the non-Q/N rich domain and 153-405 constitutes the Q/N- 
rich domain (100).  The Q/N-rich domain has been shown to be sufficient for prion 
propagation and hence is considered as the prion forming domain (PFD) for Rnq1p 
(100,101).  This domain has also been shown to form amyloid fibers (100,101).  
Additionally, a fragment of Rnq1p containing amino acids 133-405 has been shown to be 
sufficient for “infectivity”, that is, fibers generated from this fragment, when transformed 
into yeast cells, convert the cells from [rnq-] to [RNQ+] (102). The non-prion forming 
domain of Rnq1p has been suggested to be involved in self-regulation of the QN-rich 
aggregation prone domain (103).  Further, multiple mutants in the N-terminal non-prion 
forming domain of Rnq1p have been shown to inhibit the propagation of the [RNQ+] 
prion (104).     
The [RNQ+] prion has also been shown to modulate toxicity of poly-Q expansion 
proteins when expressed in yeast cells (105).  It has been shown that modulation of poly-
Q toxicity by both cis- and trans-acting polypeptide sequences depends entirely on the 
prion state of the Rnq1p (106).  As such, the [RNQ+] prion and Rnq1p provides a unique 
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system for the investigation of the effect of pre-existing misfolded proteins on the 
aggregation of other cellular proteins and its subsequent consequence on cellular 
physiology. 
Interestingly, the [RNQ+] prion can also propagate multiple variants (102,107).  
The original isolates of [RNQ+] variants were obtained spontaneously (107).  These 
variants showed differences in their ability to induce the [PSI+] prion (107).  They also 
had varied solubilities when subjected to high speed centrifugation (107).  Variants of 
[RNQ+] were also obtained when, Rnq1p aggregates were transformed into yeast (102).  
Previous work has shown very interesting interactions between variants of [PSI+] and 
[PIN+] (108,109). In particular, certain variants destabilize stable inheritance of the 
variants of the other prion (108).  
In this thesis, the focus of Chapter three is the biochemical and physical properties 
of the variants of [RNQ+] and a comparison of the physical basis of these variants with 
that suggested for [PSI+] variants (96). 
 
1.8 Interplay of chaparones and yeast prions  
Increased stress in cells caused by various environmental conditions, especially 
temperature, leads to the induced expression of a group of proteins called heat shock 
proteins (110).  Many of these heat shock proteins are molecular chaperones that function 
in protein folding, unfolding and refolding of misfolded proteins, and disaggregation of 
aggregated proteins.  More interestingly, the maintenance and propagation of yeast prions 
has been intimately linked with various chaperone systems (110).  
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Both the yeast prions discussed earlier in this chapter, [PSI+] and [RNQ+] depend 
entirely on the presence of the yeast chaperone, Hsp104p (98,111).  Interestingly, for the 
[PSI+] prion, either overexpression or inactivation of Hsp104p causes the loss of the 
prion state (111).  However, certain variants of [PSI+] are maintained only when 
Hsp104p is overproduced (112).  In contrast, [RNQ+] propagation is not affected in the 
presence of high levels of Hsp104p but reverts back to [rnq-] when HSP104 is deleted 
(77).  Interestingly, there are certain mutants of HSP104 that differentially affect [PSI+] 
and [RNQ+] prions (109,113).  
It is thought that Hsp104p functions in the propagation of prions by facilitating 
the break down of prion aggregates into smaller “seeds” or “propagons” that can be 
inherited by daughter cells.  This model suggests that it is the disaggregation activity of 
Hsp104p that is required for prion propagation in yeast (114,115).  It is possible that 
excess Hsp104p breaks down [PSI+] aggregates to soluble non-templating conformers 
and thereby rids the cell of the prion state.  However, it is yet to be determined as to how 
overproduction of Hsp104p cures the [PSI+] prion as the cells initially expression higher 
levels of Hsp104p seems to increase the size of the aggregates (114,115).   Various 
mutational analyses have been conducted by other labs in the past and novel mutational 
studies are being conducted in our lab currently to dissect the mechanism of Hsp104 
action on protein aggregation and prion maintenance (116,117). 
Other chaperones that have secondary roles in prion maintenance include the 
Hsp70s, Hsp40s and small Hsps (110,118,119).  Hsp70 family members Ssa1 and Ssa2 
when overproduced have been shown to enhance the de novo induction of [PSI+] and 
prevent curing by Hsp104p overproduction (120,121).  In fact, a direct physical 
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association of Sup35p and Ssa has been shown both in vivo and in vitro (121).  Members 
of the Ssa subfamily have been also shown to modulate poly-Q aggregation and toxicity 
when overproduced (122,123).  In contrast to Ssa proteins, Ssb proteins antagonize [PSI+] 
propagation when overexpressed in combination with Hsp104p (124).  Additionally, loss 
of SSB1 and SSB2 genes increased the spontaneous formation of [PSI+] (124).   
The Hsp40 protein, Ydj1p has been shown to promote the loss of certain variants 
of [RNQ+] (107).  Ydj1p overexpression in combination with Ssa1 has been shown to 
cure weak [PSI+] strains (125).  Sis1p, an essential Hsp40 protein in yeast has been 
shown to be required for the propagation of [RNQ+] and [PSI+] (126,127).   
The effect of yeast chaperones on protein aggregation and prion maintenance is 
complex.  Considering that the chaperones interact differently with prion aggregates 
obtained from different proteins and variants of the same prions, the specific effects that 
the various chaperones have on the aggregates (both prion and non-prion) probably 
depends on the specific properties of aggregates themselves.  Elucidating the details of 
these mechanisms may prove vital in developing strategies and/ or targets for therapeutics 
in protein misfolding disorders.  
 
1.9 Amyloid fiber polymorphisms: Effect of different solution conditions 
 A very intriguing feature of amyloid fibers (that may reflect some of the 
differences between prion variants) is that the fibers formed from the same polypeptide 
can occur in a range of structurally different morphologies.  This variation has been 
found in both in vitro preparations and biological samples (128,129).  Variation in 
clinical and pathological manifestations of several human amyloid disorders has been 
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suggested to be caused by diversity of structures of the amyloid fibers (130).  We suggest 
in Chapter 4 of this thesis that this diversity may also be responsible for differences in the 
ability of certain amyloidoses to be infectious and other to not.  Additionally, we suggest 
in Chapter 5 that some the variation within diverse fibers created from the same 
polypeptide sequence may be due to changes in environmental conditions under which 
protein aggregation was initiated.   It is important to mention here that in spite of all the 
variation, at least a small portion of the polypeptides form a cross β-sheet structure.  This 
preserves the common properties of amyloid fibers. 
 Three possibilities have been proposed as means for gross structural differences to 
arise in amyloid (131): 1) the number of protofibrils that make up the fibers, 2) relative 
orientation of the protofibrils and 3) the protofibril substructure may differ by changes in 
the underlying conformation of the subunits.  As such, sequences and specific 
interactions involved in the formation of the cross β-core may be distinct in amyloid 
fibers with different morphologies.  As mentioned earlier, the physico-chemical 
environment can substantially influence the fiber morphology created from the same 
polypeptide.  Various environmental factors have been studied in the past, such as pH of 
the solution, temperature, agitation, salts and other co-solutes (132-135).   It has been 
clearly demonstrated that for β2-m temperature and pH profoundly affect heterogeneity of 
aggregation (136).  To add to this complexity, even within the same sample, significant 
variations in fiber morphology can be detected.  Previously, it has been shown that 
certain salt conditions favor a specific ensemble of fibril structures (135).  However, 
fibrils have also proven difficult to classify based on morphology due to the variation 
between structures being more of a continuum, rather than discrete steps (137).   
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 From a disease perspective, intermediates that proteins go through in order form 
amyloid fibers are a very interesting species because it is these structures that have been 
implicated in causing toxicity to cells.  These oligomeric assemblies may present an 
avenue to either increase or decrease the variations in the structure of the amyloid fibers 
that result.  Additionally, certain structures may be susceptible to manipulation by small 
molecules to prevent toxicity. 
 Many interesting questions arise from the above set of observations. 1) How does 
a specific polypeptide chain acquire the different structures? 2) Is there a specific 
relationship between the morphologies and polypeptide sequences? 3) How do 
environmental factors affect the specific morphology and interact with different 
amyloidogenic proteins? 
 In chapter 5 of this thesis, I discuss work we have done to begin to answer these 
questions.  We have utilized six different environmental conditions and two different 
amyloidogenic proteins, Sup35p and Rnq1p to address these issues.    
 
2.0 Summary and Significance  
Protein misfolding and aggregation has been shown to play a major role in many 
diseases, including a large group of fatal neurodegenerative diseases.  In many of these 
diseases, misfolding and aggregation of the protein leads to the formation of ordered 
structures called amyloid fibers.  Phenotypic variation in some of the diseases is thought 
to be caused, in part, due to polymorphisms in the protein aggregate structures.  In spite 
of these common features, only subsets of amyloid fiber aggregates are infectious.   
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The initiating events of protein misfolding, aggregation and formation of amyloid 
fibers are not well defined.  Additionally, the effect of certain mutations in genes that 
encode proteins that participate in these diseases is not well understood.  Furthermore the 
basis for polymorphisms in amyloid fibers and their correlation to environmental 
conditions are also not known.  Most intriguingly, the differences between protein 
aggregates that are infectious and those that are benign have only started to recently be 
explored.   
The four different facets of this thesis investigate specific aspects of the above 
unanswered important questions.  In this thesis, I discuss 1) the role of a specific group of 
mutations in PrP that cause a dominant, inherited form of prion disease, 2) the physical 
basis for prion variant formation using the yeast prion [RNQ+], 3) the effect that various 
conditions have on amyloid fiber formation of the proteins, Sup35NM and Rnq1PFD, and 
4) the biochemical properties of a mutant form of Rnq1PFD, Rnq1PFD∆Hot that is 
capable of forming amyloid fibers that are both infectious and benign.   
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Abstract 
Background: Mutations in the PRNP gene account for ~15% of all prion disease cases.  
Little is understood about the mechanism of how some of these mutations in PRNP cause 
the protein to aggregate into amyloid fibers or cause disease.  We have taken advantage 
of a chimeric protein system to study the oligopeptide repeat domain (ORD) expansions 
of the prion protein, PrP, and their effect on protein aggregation and amyloid fiber 
formation.  We replaced the ORD of the yeast prion protein Sup35p with that from wild 
type and expanded ORDs of PrP and compared their biochemical properties in vitro.  We 
previously determined that these chimeric proteins maintain the [PSI+] yeast prion 
phenotype in vivo.  Interestingly, we noted that the repeat expanded chimeric prions 
seemed to be able to maintain a stronger strain of [PSI+] and convert from [psi-] to [PSI+] 
with a much higher frequency.  In this study we have attempted to understand the 
biochemical properties of these chimeric proteins and to establish a system to study the 
properties of the ORD of PrP both in vivo and in vitro conveniently.  
Results: Investigation of the chimeric proteins in vitro reveal that repeat-expansions 
increase aggregation propensity and that the kinetics of fiber formation depends on the 
number of repeats.  The fiber formation reactions are promiscuous in that the chimeric 
protein containing 14 repeats can readily cross-seed fiber formation of proteins that have 
the wild type number of repeats.  Morphologically the amyloid fibers formed by repeat-
expanded proteins associate with each other to form large clumps that were not as 
prevalent in fibers formed by proteins containing the wild type number of repeats.  
Despite the increased aggregation propensity and lateral association of the repeat 
expanded proteins, there was no corresponding increase in the stability of the fibers 
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formed.  Therefore, we predict that the differences in fibers formed with different repeat 
lengths may not be due to gross changes in the amyloid core.   
Conclusion: The biochemical observations presented here explain the properties of these 
chimeric proteins previously observed in yeast.  More importantly, they suggest a 
mechanism for the observed correlation between age of onset and disease severity with 
respect to the length of the ORD in humans.   
Background   
The aggregation of various proteins is implicated in many diseases, including 
neurodegenerative disorders [1].  Many of the aggregating proteins form amyloid fibers 
that are the hallmark of diseases such as Alzheimer’s, Parkinson’s and Huntington’s 
disease [2].  Amyloid fibers are also associated with prion diseases.  The prion protein 
(PrP) can misfold and aggregate to form amyloid fibers, leading to neurodegenerative 
prion diseases [3, 4].  The three primary means of acquiring prion diseases are as follows: 
1) infection – can be transmitted by the ingestion of meat obtained from diseased 
animals, 2) spontaneous – occurs sporadically via unknown mechanism(s) and 3) 
inherited – mutations in the PRNP gene encoding PrP [4, 5].  About 15% of prion disease 
cases are associated with mutations in the PRNP gene and ~85% of the cases are 
classified as sporadic [5].  A unique characteristic of prion diseases is that an aggregated 
form of the PrP protein can be infectious [6], however infectious forms of prion disease 
are rare in comparison to inherited and sporadic cases.  Although the mechanism of 
pathogenesis of prion diseases is not well understood, this process does not necessarily 
result from a genetic mutation [3, 7, 8].  It is hypothesized that the aggregated form of 
PrP is infectious and acts as a template to change the native conformation of PrP and 
 41
cause it to also aggregate [8].  Familial forms of prion diseases include Creutzfeldt-Jakob 
disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and Fatal Familial 
Insomnia (FFI).  Several different mutations in PRNP are associated with prion diseases, 
but the mechanisms by which the various mutations cause disease are not always clearly 
understood [5].  In this study, we use a model system created to investigate some aspects 
of an inherited form of prion disease that results from insertional mutations in PRNP to 
cause diseases such as GSS and CJD [9].   
 PrP is a 23 kD protein that can be divided into two major domains. The C 
terminus is the prion-forming domain (PFD) and is implicated in the formation of 
amyloid fibers in the infectious form of the disease [10, 11].  The N-terminal domain is 
largely unstructured; however, some mutations in this domain are linked to disease and 
influence PrP fibrillization and amyloid propagation in vitro [12].  The N-terminal region 
contains an oligopeptide repeat domain (ORD) that consists of five repeats of an eight 
amino acid peptide with the consensus sequence PHGGGWGQ [13].  Expansion of the 
ORD by the addition of two to nine extra repeats causes a dominantly inherited form of 
prion disease [5, 14-18].  The number of repeats present is inversely correlated, albeit 
weakly, with the age of onset of disease [19].  In addition, recombinant PrP peptides with 
expansions of the ORD display increased aggregation in vitro [20].  A transgenic mouse 
model of one such ORD expansion, Tg(PG14), in which the number of repeats in the 
ORD is increased to 14, develops a fatal neurodegenerative disorder [21, 22]. The disease 
manifests spontaneously, and although not infectious, the Tg(PG14) mice develop 
neurological illness that features ataxia, neuropathological abnormalities and the 
accumulation of PrP in the brain [21, 23].  However if infectious prion particles are 
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introduced into the brains of mice expressing the transgene, there is accumulation of PrP 
in the brain and the brain homogenate is actually infectious and can propogate the disease 
[22, 23].  Furthermore, the ORD has been shown to bind many divalent cations such as 
copper, manganese and zinc [24, 25].  It has been proposed that binding of these metals 
to the ORD may affect the structural properties of PrP and thereby affect disease 
progression [24].  Thus, many lines of evidence from human, mouse and biochemical 
studies illustrate a vital role for the ORD in some prion diseases. 
 Prion proteins also exist in yeast [26].  However, unlike the mammalian prion 
protein that causes disease when aggregated, yeast prions function as epigenetic factors 
of phenotypic inheritance [27-29].  One well-studied prion in yeast is the [PSI+] prion, 
whose protein determinant is Sup35p [30-32].  Sup35p is the Saccharomyces cerevisiae 
eRF3 (eukaryotic release factor 3) involved in modulating translation termination at stop 
codons in messenger RNAs.  When Sup35p is in the prion conformation ([PSI+]), the 
aggregated protein is presumably no longer functional in translation termination, 
resulting in nonsense suppression [32, 33].  
 Sup35p is a 76.5 kD protein that can be divided into three domains.  The C-
terminal domain is necessary and sufficient for the function of the protein in translation 
termination [30, 34, 35].  The amino-terminal region of Sup35p (NM) is considered the 
PFD [30, 35].  However, the minimum region required for maintainance of the prion 
[PSI+] is amino acids 1-93 [36, 37]  The N-terminal domain (N) is rich in glutamine and 
asparagine (Q/N) residues.  The middle domain (M) is rich in charged amino acids [35].   
Interestingly, the N-terminal domain of Sup35p contains an ORD that consists of five and 
a half repeats with the consensus sequence PQGGYQQYN [38] that is similar to the 
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ORD in PrP.  Deletion of even one repeat from the wild type Sup35 protein prevents 
efficient formation of the [PSI+] prion [36].  Expansion of the Sup35p repeats increases 
the frequency of conversion from the [psi-] to the [PSI+] state [38].  Previous studies have 
shown that the [PSI+] prion phenotype can be maintained in vivo when the Sup35p repeat 
region is replaced by the PrP repeat sequence [36, 39].  The Sup35p repeats were 
replaced with five, eight, 11 or 14 PrP repeats to generate chimeras referred to as SP5 
(Sup35 with 5 PrP repeats), SP8, SP11, and SP14, respectively [39].  All chimeras were 
capable of propagating a prion and maintained translation termination function in the 
non-prion state.  Interestingly, the SP14 chimeric protein spontaneously converted cells 
from the non-prion [sp14-] state to the [SP14+] prion state at a frequency that is 
approximately four orders of magnitude higher than that of the spontaneous conversion of 
wild type Sup35p from the [psi-] to the [PSI+] state.  This increase in the spontaneous 
conversion of the repeat-expanded chimera to the prion state may be due to an increase in 
the inherent propensity of the repeat-expanded proteins to aggregate and form amyloid 
fibers.  However, the interpretation of the data is complicated by the requirement for the 
[RNQ+] prion for the enhanced induction in vivo.  
 Here, we take advantage of the chimeric Sup35-PrP prion protein system to study 
the effect of the PrP repeat expansions on the in vitro aggregation of the prion protein.  
The advantage of using the Sup35-PrP chimera lies in the ability to readily study 
properties of protein aggregation both in vitro and in vivo.  By using the chimeric Sup35-
PrP protein system, the effects of mutations associated with prion disease can be assessed 
by fiber formation in vitro and compared to their in vivo behavior in yeast, and vice versa.     
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In this study, we investigate the properties of the PrP ORD and disease-associated 
repeat expansion on amyloid fiber formation in an effort to distinguish between the 
properties of an ORD with non-pathological versus pathological repeat lengths.  To this 
end, we have purified recombinant protein that encompasses the NM region of wild type 
Sup35p (Sup35NM) and that of chimeras with five (SP5NM), eight (SP8NM), 11 
(SP11NM) or 14 (SP14NM) repeats of PrP precisely substituted for the Sup35p ORD and 
characterized their kinetic, morphological and biochemical properties.  
RESULTS 
The expanded ORD of PrP decreases the lag phase of fiber formation – We purified the 
NM region of wild type Sup35p (Sup35NM) and chimeras with five (SP5NM), eight 
(SP8NM), 11 (SP11NM), and 14 (SP14NM) repeats.  The purified recombinant proteins 
were used to assess the influence of ORD repeat expansion on amyloid fiber formation by 
monitoring the change in Thioflavin-T (Th-T) fluorescence over time.  Wild type 
Sup35NM had a lag phase of ~5,000 seconds followed by a logarithmic growth phase 
(Fig. 1A).  However, in the presence of seeds (sonicated preformed fibers 2.5% w/w), the 
lag phase was completely eliminated and fiber formation occurred rapidly (Fig. 1A) as 
reported previously [40].  We then assayed fiber formation of the chimeric proteins 
SP5NM, SP8NM, SP11NM and SP14NM.  The formation of chimeric SP5NM fibers in 
an unseeded reaction showed a lag phase (~5,000 seconds; Fig. 1B) similar to that 
observed with wild type Sup35NM (Fig. 1A).  The repeat-expanded chimeras SP8NM, 
SP11NM, and SP14NM had a negligible lag phase in unseeded reactions (Fig. 1B).   
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 Figure 1. Fiber formation of ORE chimeras is faster than that with the wild type ORD of 
PrP.   Recombinant protein was diluted from denaturant (120 x) to 2.5µM and fiber 
formation was followed by Th-T fluorescence.  Graphs are plotted as %RFU (Relative 
fluorescence units) versus time.  (A) Sup35NM unseeded (solid line) and Sup35NM 
seeded with sonicated preformed fibers (dotted line).   Reaction was seeded with 2.5% 
(w/w) of preformed sonicated fibers.  (B) Unseeded reactions Sup35NM (solid line), 
SP5NM (dotted line), SP8NM (short dashed line), SP11NM (dotted and dashed line) and 
SP14NM (long dashed line).  
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Strikingly, the kinetics of fiber formation of the expanded ORD chimeric proteins in the 
unseeded reactions was similar to the kinetics of fiber formation of Sup35NM in the 
presence of pre-formed fiber seeds.  In an effort to determine if the lack of lag phase 
associated with SP14NM fiber formation was simply due to seeds forming in the 
presence 6M GdHCl, we resuspended SP14NM protein in 8M urea instead.  When 
protein was diluted out from 8M urea, we observed the same rate of fiber formation and 
no lag phase (data not shown).     
Another widely used method that enables detection of infectious prion seeds is 
protein transformation.  We tested for the presence of infectious seeds by transforming 
[psi-] yeast cells with purified SP14NM in 6M GdHCl or SP14NM sonicated fibers.  
Cells transformed with SP14NM protein that was not allowed to form fibers did not 
acquire the [PSI+] phenotype (Fig. 2) in over 200 colonies tested while 25%-30% of cells 
transformed with fibers acquired the [PSI+] phenotype (Fig. 2, data not shown).  These 
data suggest that preformed seeds of SP14NM did not exist in the presence of 6M 
GdHCl.  However, formally the possibility exists that seeds are formed that are resistant 
to both denaturants and cause the reaction to appear as a seeded reaction. We observed 
that cells transformed with SP14NM fibers formed at 4ºC and 25ºC acquired strong [PSI+] 
(Fig. 2) and weak [PSI+] (Fig. 2), respectively.  This illustrates the infectious nature of 
the in vitro formed SP14NM fibers.  The appearance of strong and weak [PSI+] strains in 
cells that were transformed with fibers formed at different temperatures is in agreement 
with previously published results for Sup35NM [41].  The concept of yeast prion strain 
variants and their basis of structural variability has been studied extensively [41-43] and 
is presumably recapitulated with our repeat expansion chimeras.   
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 In order to verify that the repeat-expanded proteins form fibers faster than the 
wild type proteins, we visualized the formation of Sup35NM and SP14NM fibers over a 
time course using transmission electron microscopy (TEM).  We were able to detect very 
few significant structures (above background) at five minutes with Sup35NM by TEM 
(Fig. 3A).   Short fibers of Sup35NM became visible at 30 minutes and the formation of 
longer fibers was observed by 150 minutes (Fig. 3B, 3C).  The TEM images obtained 
with Sup35NM at 400 minutes (Fig. 3D) were similar to images obtained after 24 hours 
of fiber formation (Fig. 7A), suggesting that the reaction had reached completion by 400 
minutes.  The TEM images supported the Th-T data which indicated that the reaction 
with wild type plateaued by ~200 minutes (Fig. 1A).  In contrast to Sup35NM, we 
observed that the repeat-expanded SP14NM formed visible short fibers as early as five 
minutes and longer fibers by 30 minutes (Fig. 3E, 3F).  TEM images of SP14NM suggest 
that fiber formation remains unchanged between 150 minutes (Fig. 3G) and 24 hours 
(Fig. 7E).   
Repeat-expanded prion protein cross-seeds the amyloid fiber formation of protein 
containing wild type repeat numbers efficiently – Prion diseases caused by oligopeptide 
repeat expansion (ORE) are inherited in an autosomal dominant manner.  Patients who 
suffer from inherited prion disease typically express one copy of the repeat-expanded 
allele and one copy of the wild type allele [7, 9].  Protein aggregates in these patients 
sometimes contain both the mutant and wild type protein [9].  One reason for the 
presence of both proteins in the aggregates could be that repeat-expanded PrP aggregates 
readily and cross-seeds the aggregation of the wild type protein.  Therefore, we tested 
whether SP14NM seeds could enhance amyloid fiber formation of either Sup35NM or  
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Figure 2.  The [PSI+] phenotype was assayed by color on YPD, growth on SD-ADE and 
curability (not shown). Control protein transformations show that protein harvested from 
either strong or weak [PSI+] cells transformed in to [psi-] cells induces the corresponding 
prion phenotype while protein harvested from [psi-] cells does not induce the prion state.  
Soluble SP14NM protein (SP14NMsol) does not induce the [PSI+] prion phenotype prior 
to fiber formation. SP14NM protein was able to induce the [PSI+] prion phenotype after 
fiber formation either at 4ºC (SP14NM4, strong strain) or 25ºC (SP14NM25, weak strain).  
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SP5NM monomers.  We observed that SP14NM does cross-seed the aggregation of both 
Sup35NM (Fig. 4A) and SP5NM (Fig. 4B) efficiently.  These data also support the 
previous suggestion that co-aggregation of wild type PrP and ORE PrP is a plausible 
factor in prion disease progression [9, 20]. 
Increasing repeat length in the ORD increases both incorporation of monomer and 
lateral association of amyloid fibers– Since the SP14NM amyloid fiber formation occurs 
almost instantaneously upon dilution from denaturant, we next asked whether there was 
any effect of adding seeds.  We observed a sharp spike in fluorescence when SP14NM 
seeds were added to soluble SP14NM monomers (Fig. 5A), suggesting that fiber 
formation did occur by templating off of the pre-formed fiber seeds added.  However, this 
spike was followed by a drop in fluorescence to a steady state level that was similar to 
that observed in the unseeded reaction.  This was a very intriguing observation as no such 
drop in fluorescence was observed in the seeded Sup35NM fiber formation reaction (Fig. 
1A).  One possible reason for the tendency of the reaction to rapidly reach a steady state 
would be the inability of the fibers to incorporate additional soluble protein.  In order to 
determine if the fiber ends were still competent for addition of soluble protein, we added 
fresh SP14NM monomer to a fiber formation reaction that had already reached the steady 
state level of Th-T fluorescence.  The addition of SP14NM monomer at the reaction 
plateau caused another spike in fluorescence (Fig. 5B), suggesting that the fibers are still 
capable of adding soluble protein.  Therefore, the plateau in fluorescence observed in 
seeded SP14NM fiber formation reactions was not likely due to an inability to 
incorporate additional monomer.  
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Figure 3. Unseeded SP14NM fiber formation is faster than Sup35NM fiber formation as 
monitored by TEM. Length of scale bar represents 100 nm.  Sup35NM (5µM) after (A) 5 
min, (B) 30 min, (C) 150 min, (D) 400 min and SP14NM (5µM) after (E) 1 min, (F) 5 
min, (G) 30 min, (H) 150 min.  
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Figure 4. Sup35NM and SP5NM are efficiently cross-seeded by SP14NM seeds.  
Recombinant protein was diluted from denaturant (120 x) to 2.5µM and fiber formation 
was followed by Th-T fluorescence. Reactions were seeded with 2.5% (w/w) of 
preformed sonicated fibers as indicated.  Graphs are plotted as %RFU versus time. (A) 
Fiber formation of Sup35NM.  (B) Fiber formation of SP5NM.  
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Alternatively, the initial spike observed in the seeded SP14NM reaction could 
arise due to fibers forming at the instant the seed is added, while the ensuing drop in 
fluorescence could result from dissociation of protein from the fibers.  The plateau would 
then be a result of the reaction reaching an equilibrium state. To address this hypothesis, 
we assessed the amount of soluble protein at the end-point of fiber formation using a 
centrifugation assay.  First, all chimeras were allowed to form fibers overnight.  Then we 
separated the amyloid fibers from the soluble protein by centrifugation and examined the 
protein in the fractions by SDS-PAGE and western blot.  We observed that the amount of 
remaining soluble protein decreased as the number of repeats increased (Fig. 6).  The 
amyloid fiber formation reaction of either SP5NM or SP8NM showed a considerable 
amount of soluble protein after an overnight incubation, as seen by the protein in the 
supernatant fraction.  However, there was little and no detectable protein in the 
supernatant from either SP11NM or SP14NM fiber formation reactions, respectively.  
The lack of soluble protein remaining in the SP14NM fiber formation reaction negated 
the hypothesis that the drop in fluorescence in seeded SP14NM reactions occurred as a 
result of dissociation of protein from the amyloid fibers over time. 
This led us to hypothesize that the spike and drop pattern of Th-T fluorescence 
seen in seeded SP14NM fiber formation reactions might be due to exclusion of Th-T 
binding over time. The increase in fluorescence occurs as Th-T initially binds the rapidly 
forming fibers and the drop may result from Th-T being occluded from the fibers as the 
reaction progresses.   In order to address this hypothesis, we returned to TEM in order to 
examine the morphology of the fibers of wild type Sup35NM and the chimeric proteins. 
Interestingly, TEM revealed a morphological difference between the Sup35NM and  
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Figure 5.  The addition of preformed seeds causes a spike in SP14NM fiber formation.  
Recombinant protein was diluted from denaturant (120 x) to 2.5µM and fiber formation 
was followed by Th-T fluorescence.  Graphs are plotted as %RFU versus time. (A) 
SP14NM unseeded (solid line) and SP14NM seeded (dotted line).  (B) Another spike in 
Th-T fluorescence is observed after the addition of more monomer (2.5µM) after the 
SP14NM fiber formation reached a plateau.  
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Figure 6.  Soluble protein is incorporated into fibers more efficiently in chimeras with 
increased number of repeats in the ORD.  Fiber formation reactions (5µM) were 
separated into supernatant (S) and pellet (P) fractions by high speed centrifugation and 
analyzed by SDS-PAGE and western blot using α-Sup35 antibodies.  Soluble protein 
remains in the supernatant fraction and the fibers are found in the pellet fraction.  (T) is 
the total reaction prior to centrifugation. 
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SP14NM fibers.  We investigated the morphology of fibers after 24 hours of fiber 
formation of all the chimeric proteins.  We observed that fibers formed from proteins 
with the wild type number of repeats, Sup35NM and SP5NM did not have a clumped 
morphology (Fig. 7A, 7B).  However, fibers formed from SP8NM, SP11NM, and 
SP14NM proteins all exhibited a highly clumped morphology by TEM (Fig. 7C, 7D, 7E).  
The repeat-expanded ORD chimeric proteins showed an increased lateral association of 
fully formed fibers as compared to the fibers formed with either Sup35NM or SP5NM.  
Furthermore, when fibers formed overnight by SP14NM were sonicated, there was an 
increase in Th-T fluorescence (data not shown).  This suggests that sonication disrupted 
the clumps and once again increased the surface area for Th-T to bind the fibers.  Such an 
increase in fluorescence was not observed when the same experiment was done with 
fibers formed from either Sup35NM or SP5NM (data not shown).  These data support the 
hypothesis that the difference in Th-T fluorescence is due to the morphological 
differences between the fibers.  As the fibers laterally associate and form large clumps, 
sites that were previously available for Th-T binding may be unable to bind to Th-T as 
they interact with other fibers.  Such Th-T occlusion would cause a drop in fluorescence.   
Prion protein repeat expansion allows fiber formation in the presence of denaturant – In 
the absence of denaturant, fiber formation of Sup35NM and SP5NM exhibits a lag phase 
of ~5,000 seconds (Fig. 1B).  However, SP8NM, SP11NM, and SP14NM form fibers 
instantaneously without an appreciable lag phase (Fig. 1B).  This suggests that expansion 
of the repeat region increases the propensity of the proteins to aggregate.  However, with 
these data we were unable to discern how the propensity to aggregate increases with the 
change in repeat length.  There may be a gradual increase in aggregation propensity with 
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an increase in repeat number or there may be a critical number of repeats after which the 
protein forms fibers without a lag phase.  To further characterize the effect that increasing 
repeat number has on protein aggregation, we assembled fibers in the presence of 
increasing concentrations of urea.  In the presence of 0.5 M urea, fiber formation of 
unseeded SP5NM had an extended lag phase of approximately 10,000 seconds (compared 
to 5,000 seconds in the absence of urea). Unseeded SP8NM had a lag phase of 
approximately 5,000 seconds (compared to no lag phase without urea) while the lag 
phases of fiber formation of either SP11NM or SP14NM were not affected by 0.5 M urea 
(Fig. 8A).  When the urea concentration was increased to 1 M in fiber formation reactions 
of SP5NM and SP8NM, the Th-T fluorescence did not reach a plateau within 30,000 
seconds (Fig. 8B), suggesting that fiber formation did not reach completion within the 
same time frame as in the absence of denaturant (Fig. 1B).  SP11NM also formed fibers 
at a much slower rate in the presence of 1 M urea (Fig. 8B).  However, the lag phase of 
SP14NM fiber formation was not affected by 1 M urea.  In the presence of 2 M urea, we 
did not detect fiber formation with any of the proteins by Th-T fluorescence (data not 
shown).  These results suggest that the propensity of the chimeric prion proteins to 
aggregate is a function of the number of repeats in the protein; as the number of repeats 
increase, the propensity of the proteins to aggregate gradually increases.   
Prion protein repeat expansion does not enhance stability of amyloid fibers – ORD-
expanded proteins aggregate to form amyloid fibers much faster than the wild type 
protein.  An interesting question that arises from this is: Do the amyloid fibers formed by  
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Figure 7.  The morphology of amyloid fibers formed from protein containing 
pathological versus non-pathological repeat lengths is distinct.  Unseeded fiber formation 
reactions (5µM) were imaged by TEM after 16 hours.  The length of scale bar represents 
100 nm.  (A) Sup35NM and (B) SP5NM have uniform dispersed fibers.  (C) SP8NM, (D) 
SP11NM and (E) SP14NM have clumped fibers. 
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Figure 8.  Expansion of the ORD enhances fiber formation in the presence of the 
denaturant urea. Recombinant protein was diluted from denaturant (120 x) to 2.5µM and 
fiber formation was followed by Th-T fluorescence.  Fiber formation of chimeric proteins 
SP5NM, SP8NM, SP11NM and SP14NM in (A) 0.5M Urea FFB (B) 1M Urea FFB is 
shown. 
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ORD-expanded proteins differ in stability?  That is, does the expansion of the ORD 
enhance fiber stability? It is possible to imagine that mutations that cause proteins to have 
a greater on-rate for fiber formation may have a slower off-rate and thereby make the 
amyloid fiber more stable. One way of measuring the stability of amyloid fibers in vitro 
is to examine their denaturation profiles.  Amyloid denaturation profiles can be evaluated 
by treating the fibers with increasing concentrations of denaturant and determining the 
concentration at which half of the protein is resolubilized.  We measured the denaturation 
profiles of the fibers formed from all of the chimeras by determining the amount of 
protein remaining aggregated after treatment with increasing concentrations of GdHCl.  
Using this method, we were able to determine the concentration of GdHCl at which the 
protein present in the pellet was depleted by approximately 50%.  Interestingly, 
approximately 50% of the pelletable protein was depleted for all the chimeras at GdHCl 
concentrations between 1.5 - 2 M (Fig. 9A), suggesting that the ORD expansion does not 
enhance the stability of fibers.  We also measured stability of the chimeras by monitoring 
Th-T fluorescence after treatment with increasing concentrations of GdHCl and observed 
that the loss of Th-T fluorescence was similar for all chimeric proteins and mirrored the 
centrifugation results (data not shown). Next, we examined fiber stability in a 
temperature solublization assay.  We treated fibers across a temperature gradient from 
25ºC to 95ºC at 10ºC intervals in the presence of 2% SDS.  We observed that for all the 
fibers 50% of the protein becomes soluble between 55ºC - 65ºC (Fig. 9B).  Taken 
together, these data suggest that the stability of the amyloid fibers formed by the chimeric 
proteins is the same, irrespective of the ORD repeat length.   
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Figure 9.  The stability of the prion protein fibers is not enhanced by expansion of the 
repeat domain.  (A) Fibers were formed overnight, treated with GdHCl denaturant and 
then separated into soluble and pellet fractions by centrifugation (16,000 x g).  Samples 
were analyzed by SDS-PAGE and western blotted using α-Sup35 antibodies.  Bands were 
quantified using ImageJ software. (B) Fibers of SP5NM (●), SP8NM (○), SP11NM (▼) 
and SP14NM (∆) were formed overnight, treated across a temperature gradient in the 
presence of 2% SDS. Following SDS-PAGE and western blot, gel bands were quantified 
using ImageJ software and and best fit lines were graphed using SigmaPlot software.   
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DISCUSSION 
In this study, we characterized the biochemical properties of a set of chimeric 
prion proteins wherein the ORD of Sup35p was replaced with that of PrP.  The chimeric 
prion proteins were created by substituting the endogenous Sup35p ORD with the repeat 
domain of PrP containing five, eight, 11 and 14 oligopeptide repeats [39].  The repeat-
expanded proteins show a remarkable set of properties that highlight their enhanced 
ability to aggregate and form amyloid fibers in vitro.  These data agree with work done 
by others in which recombinant PrP (rPrP) with ORD expansions exhibit an enhanced 
ability to form amyloid fibers with increasing number of repeats [20, 44].  Our data also 
support previous work done with transgenic mice (Tg(PG14)) that express PrP harboring 
nine additional octapeptide repeats.  These mice manifest a spontaneous form of prion 
disease [21].  Although the spontaneous form of the disease in the Tg(PG14) mice is not 
infectious, the protein aggregates and the animals display many of the histopathological 
hallmarks that are characteristic of prion diseases in mammals [23]. 
 In humans, there is a high degree of heterogeneity with respect to the age of onset 
and disease progression in people that have mutations in the PRNP gene [19, 45, 46].  
There is a weak inverse correlation between the number of repeats and the age of onset of 
disease [19].  Further, repeat-expanded proteins have also been proposed to interact with 
the wild type PrP protein.  Examination of amyloid plaques from patients with one copy 
of wild type PrP and one copy of mutant PrP demonstrated the presence of both the wild 
type and the mutant forms of the protein in the same plaques [9].  It has also been shown 
that mixing repeat-expanded rPrP with wild type rPrP enhances fiber formation of  wild 
type rPrP [20]. These data suggested that there may be co-aggregation or cross-seeding 
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between the mutant and wild type proteins.  Our data also supports the cross-seeding 
model of disease progression since SP14NM shows efficient cross-seeding of both 
Sup35NM and SP5NM. 
We observed that an increase in the number of repeats enhanced the ability of the 
protein to form fibers to the extent that the lag phase observed during most amyloid fiber 
formation reactions was lost.  In addition, the proteins harboring repeat expansions had 
an enhanced ability to form fibers in the presence of denaturant.  Interestingly, comparing 
our data to a recent study suggests that the presence of heterogeneous repeats, that is, a 
combination of one Sup35p repeat with eight repeats from the PrP protein, forms amyloid 
fibers slower than having eight repeats from PrP only (Fig. 1B) [25]. This suggests that 
the enhanced amyloid formation with repeat expansion requires homogenous repeats. 
Strikingly, our data suggests seeding of fibers with proteins having different (Sup35p or 
PrP) repeats appears to be as efficient as seeding with proteins that harbor same repeats 
(Fig. 4B).   
Previous work by Serio et al. suggested a nucleated conformational conversion 
model of amyloid fiber formation of Sup35NM [47].  An important aspect of this model 
is that the rate limiting step for fiber formation, manifested as the lag phase, is the 
conformational conversion of the nucleus to establish a competent seed.  One implication 
of this model is that rate of fiber formation is not linearly dependent on initial 
concentration of protein.  Serio et al. showed that the lag phase of Sup35NM fiber 
formation was not affected significantly by the initial protein concentration.  We 
observed that the lag phase of SP14NM fiber formation, albeit an extremely short lag 
phase, is also not affected by initial protein concentration.  In fact, even when the 
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concentration of SP14NM protein was only 0.25 µM in unseeded fiber formation 
reactions, the lag phase of fiber formation was identical to that of 5 µM protein (data not 
shown).  Our kinetic data suggest that the SP14NM nucleus has an enhanced ability to 
undergo conformational conversion to the extent that the lag phase of fiber formation is 
virtually eliminated.  As previously suggested [42], one mechanism that could explain the 
decrease in lag phase for fiber formation is that the expanded ORDs have transient β-
sheet structures that are formed due to intramolecular contacts, which may reduce the 
number of intermolecular contacts required to obtain a stabilized structure to nucleate 
fiber formation.  This would suggest that if a monomer can undergo the appropriate 
conformational changes and maintain that conformation through intramolecular contacts, 
then the protein may not need to form oligomers in order to form fibers.  Currently, it is 
unclear if the growth of amyloid fibers in general occurs through linear addition of 
monomers or intermediate fibers [48, 49].  Different amyloidogenic proteins may have 
distinct mechanisms for the growth of amyloid fibers.  Work done by others suggests that 
fibers formed by Sup35NM occurs by monomer addition [49], however, in the case of the 
A-beta peptide, an oligomeric intermediate may be necessary for fiber growth [50, 51].  
One current model for the growth of poly-Q peptides suggests that a single molecule, 
after undergoing conformational conversion, may act as a nucleus capable of templating 
the addition of monomers, thereby resulting in the growth of amyloid fibers [48]. 
Therefore, it is plausible that for PrP molecules with expanded ORDs, the mechanism of 
amyloid fiber assembly and growth changes such that the formation of an oligomer for 
initiation or growth of fibers is no longer required.   
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 In addition to the ability of repeat-expanded proteins to form a competent seed 
more readily, a difference in the pathological and non-pathological repeat expansions 
may be in the efficiency with which monomer is added to the fibers.  Our data from the 
centrifugation assay suggests that the ability of the conformationally-converted nucleus to 
incorporate soluble protein increases as the number of repeats increase.  Currently, a 
debatable idea in the amyloid field is the existence of a critical concentration in amyloid 
fiber formation reactions.  It has been suggested that the addition of monomer to the 
fibers may be reversible [52].  Therefore, by assaying the amount of monomer remaining 
at the end point, we could potentially determine the relative critical concentrations [53].  
As such, our data from the centrifugation assay may also suggest that as the number of 
repeats in the ORD increases, the critical concentration decreases.  However, we do not 
know if these reactions are in fact reversible.  
Since the repeat-expanded proteins form fibers faster and incorporate monomer 
more efficiently, we hypothesized that the fibers formed may also be more stable.  
However, the increased repeat length did not alter amyloid stability as assessed by 
denaturation in GdHCl or resolubilization by heat treatment.  We observed no significant 
shift in the concentration of GdHCl or the range of temperature that resolublized 50% of 
the fibers formed by the chimeras.  This suggests that, irrespective of which mutant 
repeat expansion protein is found from patient to patient, the clearance of the aggregates 
might be equally challenging to the cellular machinery.  One reason for the lack of 
difference in stability might be that the amyloid core of the fibers does not change 
significantly between fibers formed with the various repeat-expanded monomers.  We 
crudely assessed changes in the amyloid core of the fibers by treating the fibers with 
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various proteases and determining the pattern of protease resistant fragments.  We 
observed similar patterns of protease resistant fragments for all of the ORD-expanded 
proteins (chymotrypsin, V8, proteinase K; data not shown).  This suggests that the 
amyloid core of all the fibers, regardless of the monomer used to form the fibers, might 
be the same.  In order to conclusively determine the amyloid core of all these proteins, 
however, more sensitive biophysical assays are required.  
 From our previous in vivo experiments [39], we noted that SP14NM can maintain 
the [SP14+] prion phenotype in weak and strong variants similar to the wild type [PSI+].  
However, a very unique characteristic of the [SP14+] prion lies in its ability to 
interconvert between weak and strong variants at a high frequency.  One explanation for 
the ability of SP14 to be able to interconvert readily may be that the amyloid core does 
not change significantly between the two variants.  Therefore, the protein would readily 
be able to adopt either conformation and thereby switch variants at a high frequency.  
This differs from wild type Sup35p, where weak and strong strains of the [PSI+] prion 
have different amyloid cores [42].  However it is important to note that another study 
suggests that the strain variants may actually not have significantly different amyloid 
cores [54].  The strain variants observed in yeast can be used as a model to study the 
phenotypic heterogeneity that is exhibited by strains of prion disease.  The ability of 
[SP14+] prion to interconvert between variants rapidly may provide an avenue to 
investigate the mechanisms underlying the high degree of phenotypic heterogeneity 
observed with prion diseases that arise due to repeat expansions in PRNP.   
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Conclusion 
In summary, biochemical characterization of the repeat expanded proteins 
demonstrated that the proteins harboring repeat expansions of pathological length have a 
greater propensity to aggregate and have a considerably shorter lag phase in fiber 
formation.  The morphology of the fibers is also different between the non-pathological 
and pathological repeat expansions.  Amyloid fibers formed with repeat-expanded 
proteins clump into large aggregates, whereas the fibers formed by proteins that do not 
have repeat expansions do not laterally associate to the same extent.  Additionally, 
chimeras with the disease-associated repeat expansions proved to be more efficient at 
converting soluble protein into the aggregated state than the proteins containing wild type 
repeat numbers.  In spite of the differences between the proteins with respect to fiber 
formation rate and morphology, the pattern of protease resistance, presumably indicative 
of the amyloid core, remained the same in all chimeric proteins.  In addition, the fibers 
formed from all proteins showed similar denaturation and solubilization profiles when 
treated with guanidine hydrochloride (GdHCl) or heat.  Together, our data suggest that 
the expansion of the ORD in PrP results in an increased propensity of the protein to 
convert from the native conformation to an aggregated conformation, but does not alter 
the stability of the amyloid fibers formed.   
Methods 
Protein expression and purification of recombinant proteins –  Sup35NM was purified as 
reported previously [55].  SP5NM, SP8NM, SP11NM and SP14NM were subcloned 
(from [39]) into the vector pET22.  Protein was expressed in BL21(DE3)pLysS 
Escherichia coli cells grown in CircleGrow® medium containing chloramphenicol 
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(34µg/ml) and ampicillin (100 µg/ml).  Protein expression was induced with 1mM IPTG, 
at OD600~0.6 at 24ºC for four and a half hours.  The bacterial pellet was resuspended in 
buffer A (8M urea, 10mM Tris-HCl, pH 7.5) and gently agitated at room temperature for 
20 minutes.  The cell debris was removed by centrifugation for 30 minutes at 17,000 rpm 
in a Sorvall SS-34 rotor.  The supernatant was loaded onto a Q-Sepharose (GE 
HealthCare) column and the protein was eluted with a linear gradient of sodium chloride 
(0 - 1M NaCl).  Fractions containing the protein were loaded onto a hydroxyapatite 
column (BIO RAD) equilibrated with buffer C (8M Urea, 5mM KPO4, pH 6.8).  The 
protein was eluted with a linear gradient of potassium phosphate (5-500mM).  Fractions 
containing the protein were determined by SDS-PAGE and coomassie staining.  The 
fractions containing the protein were pooled and dialyzed against Buffer A and stored in 
methanol at -80ºC.  
Amyloid Fiber Formation Kinetics –   Recombinant protein was methanol-precipitated 
and resuspended in 6M GdHCl.  Protein concentration was determined by measuring the 
OD at 280nm.  The protein was diluted 120-fold in FFB buffer (150mM NaCl, 5mM 
KPO4, pH 7.5) for fiber formation assays.  Fiber formation was followed by monitoring 
Thioflavin-T binding (100-fold excess).  Thioflavin-T fluorescence was continuously 
measured using PTI Quantamaster spectrofluorometer (Photon Technology International, 
Inc., Santa Clara, CA).   
Electron Microscopy –Samples of fibrillar Sup35NM, SP5NM, SP8NM, SP11NM and 
SP14NM were allowed to settle onto freshly glow-discharged 200 mesh carbon-formvar 
coated copper grids for 5 minutes.  Grids were then rinsed twice with water and stained 
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with 1% uranyl acetate (Ted Pella) for one minute.  Samples were viewed on a JEOL 
1200EX transmission electron microscope (JEOL USA). 
Centrifugation Assay – Amyloid fibers were formed by incubating recombinant protein 
diluted 120-fold in FFB overnight at room temperature while rotating end-over-end.  The 
reaction was separated into pellet and supernatant fractions by centrifugation (16,000 x g, 
20 minutes).  The total, supernatant and pellet fractions were separated by SDS-PAGE 
and analyzed by western blot using α-Sup35 antibodies.  
GuanidineHydrochloride (GdHCl) denaturation profile – Recombinant protein was 
diluted 120-fold in FFB and incubated at room temperature on a rotator overnight.  The 
fibers were treated with increasing concentrations (0-2M) of GdHCl for 30 minutes.  The 
treated fibers were then separated into supernatant and pellet fractions by centrifugation 
(16,000 x g, 20 minutes).  The pellet fractions were separated by SDS-PAGE and 
analyzed by western blot using α-Sup35 antibodies.  The band intensities were quantified 
using ImageJ software.  
Temperature resolubilization assay – Recombinant protein was diluted 120-fold in FFB 
and incubated at room temperature on a rotator overnight.  These fibers were then 
incubated across a temperature gradient (25ºC - 95ºC, 10ºC intervals) for 5 minutes in the 
presence of 2% SDS.  After the heat treatment, the samples were analyzed by SDS-PAGE 
and western blot.  The amount of protein that entered the gel was determined by 
quantifying the bands using ImageJ software.    
Protein transformation – Protein transformation into 74-D694 yeast strain was conducted 
as described in Ref. [56]. 
Abbreviations 
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 IPTG: isopropyl-beta-D-thiogalactopyranoside, ORD: Oligopeptide Repeat Domain, 
ORE: Oligopeptide Repeat Expansion, PFD: Prion Forming Domain, PrP: Prion Protein, 
SDS-PAGE: Sodium Dodecyl Sulphate- PolyAcrylamide Gel Electrophoresis, TEM: 
Transmission Electron Microscopy, Th-T: Thioflavin-T.  
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SUMMARY 
 
Variation in pathology of human prion disease is believed to be caused, in part, by 
distinct conformations of aggregated protein resulting in different prion strains.  
Several prions also exist in yeast and maintain different self-propagating structures, 
referred to as prion variants.  Investigation of the yeast prion [PSI+] has been 
instrumental in deciphering properties of prion variants and modeling the physical 
basis of their formation.  Here, we describe the generation of specific variants of the 
[RNQ+] prion in yeast transformed with fibers formed in vitro in different 
conditions.  The fibers of the Rnq1p prion-forming domain (PFD) that induce 
different variants in vivo have distinct biochemical properties. The physical basis of 
propagation of prion variants has been previously correlated to rates of aggregation 
and disaggregation.  With [RNQ+] prion variants, we found that the prion variant 
does not correlate with the rate of aggregation as anticipated but does correlate with 
fragility.  Interestingly, we found that there are differences in the ability of the 
[RNQ+] prion variants to faithfully propagate themselves and to template the 
aggregation of other proteins.  Incorporating the mechanism of variant formation 
elucidated in this study with that previously proposed for [PSI+] variants has 
provided a framework to separate general characteristics of prion variant 
properties from those specific to individual prion proteins.    
 
Prion diseases are fatal neurodegenerative disorders that affect many mammals.  
Prions are responsible for diseases such as scrapie in sheep, bovine spongiform 
encephalopathy (BSE) in cows and Creutzfeldt-Jakob disease in humans (1).  These 
diseases are linked to either mutations in the gene encoding the prion protein (PRNP) or 
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aggregation of the prion protein (PrP) itself (2,3).  Self-propagating aggregates of PrP are 
implicated in the infectious transmission of prion disease among mammals (4).  One 
interesting feature of prion diseases lies in the apparent heterogeneity of clinical 
symptoms and disease pathology (5-7).  It has been hypothesized that this heterogeneity 
in pathology is partly due to the existence of different prion strains (8).  The mechanism 
of prion strain generation is not entirely understood, but is an important aspect of prion 
disease.  Elucidating mechanisms that dictate the generation of prion strains is crucial to 
understanding the biology underlying prion diseases, protein misfolding, and aggregation.   
Naturally occurring prions that exist in fungi such as the budding yeast 
Saccharomyces cerevisiae are not associated with disease, but act as a mechanism to alter 
phenotype.  Recent studies have uncovered several prion-like proteins in yeast (9-13).  
The three extensively characterized prions in yeast are the [PSI+], [RNQ+] and [URE3] 
prions (14-16).  The [PSI+] prion manifests as a result of the aggregation of Sup35p 
(17,18),  which is the S. cerevisiae eukaryotic release factor 3 (eRF3) (19).  In the [psi-] 
state, Sup35p binds Sup45p and this complex is required for translation termination at 
stop codons (20).  In the [PSI+] state, however, much of the Sup35p is in the aggregated 
state and not available to function in translation termination (17).  A premature stop 
codon in a metabolic pathway, such as that in the ade1-14 allele, provides a convenient 
method of detecting the [PSI] state of yeast cells.  Yeast grown on nutrient-rich media 
that harbor the ade1-14 allele are white in color in the [PSI+] state, but red in color in the 
[psi-] state due to the accumulation of a metabolic intermediate in the adenine 
biosynthetic pathway (21).  Yeast can maintain different variants of the [PSI+] prion and 
these cause different levels of read through of the ade1-14 premature stop codon that 
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correlate to the amount of aggregated Sup35p (22-24).  This results in different levels of 
pigment accumulation in cells and weaker strains of [PSI+] manifest as shades of pink 
(24).  This phenotype has proven very useful in investigating the mechanism of prion 
variant generation.  
The structure of different [PSI+] prion variants have been revealed by biophysical 
and nuclear magnetic resonance (NMR) studies on conformationally-distinct fibers of the 
prion forming domain (PFD) of Sup35p (Sup35NM) formed in vitro at different 
temperatures (25-28).  These studies suggest that the protected amyloid core of the strong 
variant is short relative to the amyloid core of the weak variant.  A model designed to 
explain the propagation of prion variants related structural and biochemical properties of 
amyloid fibers to the prion variant phenotype (29).  This model suggests that the 
propagation of prion variants can be explained by differences in the rate of fiber growth 
and sensitivity to shearing.  Since the addition of new protein appears to occur on fiber 
ends (30,31), it follows that the most efficient propagation requires more free ends to 
template the addition of new protein.  Thus, more free ends may relate to a faster rate of 
aggregation.  The mechanism for prion variant generation has been proposed primarily 
based on work conducted using Sup35NM and the [PSI+] prion.   
Two other prions in yeast, [URE3] and [RNQ+], have also been reported to 
display variant phenotypes (32,33).  The [URE3]  prion in S. cerevisiae is propagated by 
the Ure2 protein (16).  Recombinant Ure2p can form fibers in vitro and when 
transformed into yeast can induce different variants of the [URE3] prion (33).  The 
[RNQ+] prion is caused by the aggregation of the Rnq1 protein (34).  In the [rnq-] state, 
the Rnq1 protein has no known function.  However, in the [RNQ+] state, aggregated 
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Rnq1p facilitates the induction of the [PSI+] prion (35-37).  [RNQ+] also exists as 
different variants (38) that appear when recombinant Rnq1p fibers are transformed into 
yeast (39).  However, the generation of specific [RNQ+] variants by altering the 
conditions of in vitro amyloid formation has not been investigated.  As such, the physical 
basis for the generation of [URE3] and [RNQ+] variants has not been described and it 
remains to be determined if the properties described for [PSI+] variants can be 
generalized.  
We have taken advantage of the [RNQ+] reporter protein (RRP) previously 
described by our lab to phenotypically assess the [RNQ+] prion status as well as [RNQ+] 
variants (40).  The RRP molecule is a chimeric protein with the proposed PFD of Rnq1p 
(amino acids 153-405) fused to the translation termination domain of Sup35p (the MC 
region, amino acids 124-685) (41,42).  The RRP fusion presumably co-aggregates with 
Rnq1p in the [RNQ+] state which results in prion-dependent nonsense suppression.  As 
such, this provides a phenotypic assay for the [RNQ] state.  This assay allowed us to 
detect both intragenic and extragenic effectors of [RNQ+] propagation (40,43).  We found 
that the level of nonsense suppression afforded by RRP changes with [RNQ+] prion 
variants and this enables us to distinguish variants by phenotype. 
In this study, we created and characterized variants of the [RNQ+] prion by 
controlling conditions of fiber formation and transforming the fibers into yeast strains 
with Rnq1p in the non-prion state, [rnq-].    We show that the proposed PFD of Rnq1p 
forms amyloid fibers with distinct characteristics when generated in different conditions.  
Additionally, infection of these fibers into yeast induces different [RNQ+] prion variants 
in vivo.  Each [RNQ+] variant maintains and propagates a unique set of characteristics in 
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vivo and in vitro.  Finally, our data suggests the existence of both similarities and 
differences between the mechanisms that dictate [RNQ+] and [PSI+] variant propagation.  
RESULTS 
Temperature has a  profound effect on the  kinetics of Rnq1PFD fiber formation- 
We purified recombinant Rnq1PFD in 8 M Urea as described in experimental procedures.  
The purified Rnq1PFD protein formed amyloid fibers when diluted out of denaturant.  
The length of the lag phase of fiber formation is a parameter that can be used to measure 
the ability of the protein to aggregate and is one determinant for prion variant formation; 
a longer lag phase indicates a reduced ability to aggregate.  In order to create [RNQ+] 
prion variants, we used different temperatures to generate structural variation in the fibers 
of Rnq1PFD.  We followed fiber formation of Rnq1PFD at 25○C and 37○C using a 
Thioflavin-T fluorescence assay.  At 25○C, Rnq1PFD fibers had a lag phase of ~470 
minutes followed by a logarithmic growth phase (Fig. 1A).  In contrast, fiber formation 
of Rnq1PFD at 37○C had a shorter lag phase of ~300 minutes.   
The ability of seeds to enhance the conversion of monomeric protein into fibers is 
an important feature of nucleated conformational conversion for amyloid fiber formation 
(44).  We formed Rnq1PFD fibers at 25○C and 37○C and tested the ability of the fibers to 
act as seeds and template the addition of freshly diluted monomeric Rnq1PFD.  
Interestingly, even though Rnq1PFD fiber formation occurs with a shorter lag phase at 
37○C, the seeds obtained from fibers formed at 25○C were more efficient at templating 
new fiber formation at both 25○C and 37○C (Fig. 1B and 1C).  Seeds obtained from fibers 
formed at 37○C also enhanced fiber formation reactions but were less efficient at seeding 
Rnq1PFD monomer at either temperature (Fig. 1B and 1C).   
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  FIGURE 1.  Fiber formation of Rnq1p is faster at higher temperatures and 
enhanced by the addition of pre-formed seeds.  Purified Rnq1PFD was diluted from 
denaturant (75-fold) to 4 µM and fiber formation was followed using Th-T fluorescence.  
Graphs are plotted as %RFU (relative fluorescence units) versus time.  (A) Rnq1PFD 
unseeded at 25○C (black squares) and 37○C (grey circles).  (B) Rnq1PFD fiber formation 
at 25○C unseeded (black squares), with 5% seeds formed at 25○C (grey circles), and with 
5% seeds formed at 37○C (open triangles).  (C) Rnq1PFD fiber formation at 37○C 
unseeded (black squares), with 5% seeds formed at 25○C (grey circles) and with 5% 
seeds formed at 37○C (open triangles).  Graphs are representative of at least three 
independent trials.  
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Rnq1PFD fibers formed at different temperatures induce distinct distributions of 
prion variants- Prion proteins in yeast can maintain different variants of the prion state 
that are a consequence of different self-propagating structures (45).  The variants differ 
from each other based on their phenotype, the ratio of soluble to aggregated protein, and 
their ability to maintain and propagate the prion (23,24,38).  Previous work has 
extensively characterized variants of the [PSI+] prion generated in vitro (25-27,29,46,47).  
Variants of the [RNQ+] prion have also been characterized in vivo and display different 
abilities to induce the [PSI+] prion (38,48).  However, these variants arose spontaneously 
and were originally referred to as [PIN+] strains for [PSI+] induciblity (37,49).  
Additionally, some variants of [PIN+] were acquired when fibers of Rnq1PFD were 
transformed into [rnq-] yeast, but these were not characterized (39).  Characterization of 
[RNQ+] variants has been limited since the only methods to assay the [RNQ+]/ [PIN+] 
status of yeast cells involved either [PSI+] induction or Rnq1p solubility assays.  In our 
lab, we have been able to circumvent some of these tedious procedures by taking 
advantage of the previously described RRP ([RNQ+] Reporter Protein), which enables the 
use of a colony color assay to determine the presence of different prion variants of 
[RNQ+].  We found that RRP not only reported on the presence of the [RNQ+] prion, but 
also showed changes in phenotype depending on the [RNQ+]/[PIN+] variant ((40) and Fig. 
2A).  High [PIN+] and [pin-] are readily discernible from low [PIN+] and medium [PIN+] 
when RRP-expressing strains are grown on nutrient rich media. Low [PIN+] and medium 
[PIN+] strains are phenotypically similar to each other in this assay.  
 In order to create [RNQ+] variants for characterization, we first asked whether 
amyloid fibers of Rnq1PFD formed at different temperatures corresponded to the 
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generation of different prion variants, as previously observed with Sup35NM and [PSI+] 
(47,50).  We transformed [rnq-] 74-D694 cells expressing both wild type RNQ1 and the 
RRP chimeric protein with amyloid fibers of recombinant Rnq1PFD formed at 18○C, 
25○C, and 37○C.  Transformants were picked, diluted, and spotted on plates to assess 
phenotype.  We scored the transformants that turned white, light pink, or dark pink as 
strong, medium, or weak [RNQ+] variants, respectively (Fig. 2B and Table 1).  We also 
correlated the colony color phenotype of the variants to their growth on media lacking 
adenine (SD-ade).  Transformants were also grown on media containing guanidine 
hydrochloride (GdnHCl), which inactivates Hsp104 (51) and cures all variants of the 
[RNQ+] prion.  [RNQ+] variants were verified for curability on media containing GdnHCl 
using color as an indicator of change in nonsense suppression.  [RNQ+] RRP strains 
converted from either white or pink to red, and the cured strains remained red upon 
removal from media containing GdnHCl.  Rnq1PFD fibers formed at 18○C only induced 
strong and medium variants of [RNQ+] when transformed into [rnq-] cells (Table 1).  
Fibers formed at 25○C induced weak, medium, and strong [RNQ+] variants when 
transformed into [rnq-] cells.  In contrast, cells infected with fibers formed at 37○C 
yielded primarily medium and weak [RNQ+] variants and very few strong [RNQ+] 
variants.  These data suggest that the temperature at which fibers were formed in vitro 
influenced the distribution of [RNQ+] variants propagated in cells.  Specifically, 
increasing the temperature decreased the fraction of strong [RNQ+] variants and increased 
the weak variants of [RNQ+]. 
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FIGURE 2. RRP differentiates [RNQ+]/ [PIN+] variants (A) Yeast strains expression 
the RRP reporter display different levels of nonsense suppression in [PIN+] variants. (B) 
Transformation of Rnq1PFD amyloid fibers into [rnq-] yeast induces variants of the 
[RNQ+] prion.  The [RNQ+] phenotype was assayed using the RRP reporter to show color 
on YPD, growth on SD-ade, and curability by growth on media containing GdnHCl.  
Colony color on YPD is indicative of different levels of suppression of the ade1-14 
premature stop codon to produce Ade1p.  [RNQ+] prion variants co-aggregate with RRP 
and cause different phenotypes (color on YPD).  The strength of the variants is also 
reflected by their ability to grow on SD-ade medium. 
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Distribution of [RNQ+] variants 
Weak Medium Strong
Table 1 
18 ° C  0 25 75
15 46 3925 ° C 
329 6837 ° C 
 
Table 1. Distribution of [RNQ+] prion variants. Yeast colonies that resulted from 
infection of Rnq1PFD fibers formed at 18○C, 25○C, and 37○C were grouped into weak, 
medium, and strong [RNQ+] strains based on RRP-mediated colony color (on YPD) and 
growth on medium lacking adenine (SD-ade).  The numbers in the table reflect the 
percentage of variants obtained by infectivity assays after counting over 300 transformed 
colonies from more than three experiments for each temperature at which fibers were 
formed. 
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Rnq1PFD fibers formed at different temperatures are differentially stable-  In the 
case of Sup35NM and the [PSI+] prion, weaker variants have a longer amyloid core and 
stronger variants have a shorter amyloid core (25,26).  The length of the core positively 
correlates with the stability of the amyloid fibers.  Additionally, the more stable amyloid 
fibers with a longer core propagate weaker prion variants while less stable fibers with a 
shorter core propagate stronger prion variants. 
We next asked if  the stability of the amyloid fibers correlated to the [RNQ+] 
variants induced in a manner similar to the observations with [PSI+] and Sup35NM.  
Therefore, we used thermostability to determine the relative stability of Rnq1PFD fibers 
formed at different temperatures.  We formed fibers at 18○C, 25○C, and 37○C and 
subjected them to increasing temperatures in 2% SDS.  We then analyzed the soluble 
protein by SDS-PAGE and western blot.   We found that fibers formed at 18○C were 
labile and showed ~50% disruption at 65○C (Fig. 3).  Fibers formed at 25○C were slightly 
more stable and showed ~50% dissociation at 75○C.  Rnq1PFD fibers formed at 37○C 
were the most stable and required 85○C to dissociate.  Thus, stronger amyloid fibers yield 
weaker prion variants and this trend recapitulates the data observed previously for 
Sup35NM.  
Transmission electron microscopy (TEM) reveals dramatic morphological 
differences in Rnq1PFD fibers- The observed dramatic differences in kinetics and 
stability of amyloid fibers of Rnq1PFD formed at different temperatures and their ability 
to induce different variants of [RNQ+] led us to hypothesize that the morphology of the 
Rnq1PFD fibers formed at these temperatures may be distinct.  In order to determine if 
there are gross morphological differences between the Rnq1PFD fibers formed at 18○C, 
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 FIGURE 3.  Rnq1PFD fibers formed at higher temperatures are more stable.  
Preformed fibers were treated across a temperature gradient in the presence of 2% SDS.  
Following SDS-PAGE and western blot, the amount of soluble Rnq1PFD was quantified 
and the results were graphed as a percentage of total protein at 95○C using OriginPro 6.1 
with a sigmoidal fit function. 
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FIGURE 4.  The morphology of amyloid fibers formed from Rnq1PFD at different 
temperatures is distinct.  Amyloid fibers of Rnq1PFD formed in vitro were imaged by 
TEM.  The scale bar represents 200 nm. (A) 18○C fibers are short and curly (B) 25○C 
fibers are long and curvy, and (C) 37○C fibers are long and bundled. 
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25○C, and 37○C we obtained TEM images of these amyloid fibers.  In fact, we did 
observe significant differences in the morphology of the fibers formed at the different 
temperatures.  We noted that the Rnq1PFD fibers formed at 18○C were short and curly 
(Fig. 4A) compared to the long fibers formed at 25○C (Fig. 4B).  Lastly, the fibers formed 
at 37○C were also long and appeared to be more heavily bundled with one another as 
compared to the fibers formed at 25○C (Fig. 4C).  These results indicate that temperature 
has a profound impact on the properties of the amyloid fibers formed by Rnq1PFD. 
  [RNQ+] prion variants have distinct protein aggregation and propagation 
properties in vivo Variants of the [PSI+] prion have differential abilities to faithfully 
propagate the prion through mitosis (24).  We utilized the RRP marker to determine the 
relative mitotic stability of the [RNQ+] prion variants.  We grew the three different 
variants in liquid media overnight and plated them on rich media to assess [RNQ+] 
stability by color.  The colonies that did not maintain the prion through mitotic division 
turned red and were counted and plotted as a fraction of the total number of colonies (Fig. 
5A).  The strong [RNQ+] prion variant propagated the prion with nearly 100% fidelity 
and rarely lost the prion phenotype.  In comparison, the medium [RNQ+] variant lost the 
prion in ~19% of the progeny and the weak [RNQ+] variant lost the prion in almost 40% 
of the progeny.  The loss of the [RNQ+] prion was verified by conducting Rnq1p 
solubility assay on a subset of candidate [rnq-] cells for each variant.  Thus, the stability 
of prion propagation is correlated to the strength of the prion variant and is similar to 
what has been observed with the [PSI+] prion. 
Even though there are differences in mitotic stability, all prions should be 
transmitted in a non-Mendelian fashion via mating and meiosis (52).  To verify that the 
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cells infected with in vitro formed fibers of Rnq1PFD truly harbor self-propagating prion 
elements, we tested the transmission of the prion.  We mated the transformed cells 
harboring different variants of the [RNQ+] prion to [psi-] [rnq-] cells.  The diploids that 
we obtained were [psi-] [RNQ+] and red in color because wild type Sup35p does not 
aggregate with RRP and allows for faithful termination of translation (data not shown).  
We sporulated the diploids to determine if the [RNQ+] prion variants were faithfully 
inherited in meiotic progeny as expected for the prion state.  We then performed Rnq1p 
solubility assays on at least three complete tetrads from each strain.  We noted that in 
each case, the [RNQ+] prion was inherited in a non-Mendelian fashion with all four 
progeny being [RNQ+] (data not shown).  
 Prion variants of both [PSI+] and [RNQ+] have also been shown to display 
differences in the ratio of soluble to aggregated protein (23,38).  In order to determine 
whether the different [RNQ+] variants that we had classified based on phenotype had 
corresponding biochemical differences, we performed Rnq1p solubility assays on the 
variants (Fig. 5B).  In cells containing the weak [RNQ+] variants, most of the protein was 
in the soluble fraction and a small amount of Rnq1p was in the pellet fraction.  In the 
medium [RNQ+] variants, a small portion of the protein was soluble, while most was 
found in the aggregated pellet fraction.  However, in the strong [RNQ+] variant, almost all 
of Rnq1p was aggregated and very little protein was found in the soluble fraction.  
Interestingly, this variant-dependent change in solubility was reproducible in fresh 
transformants but was not as apparent in new meiotic progeny (data not shown).  
However, the [RNQ+] solubility assay has not always provided a robust measure of 
differences in prion variants (38,40).  
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 FIGURE 5.  Variants of the [RNQ+] prion show distinct propagation and 
aggregation properties in vivo.  (A) Mitotic stability of the [RNQ+] prion was dependent 
on the strength of the variant.  The weak [RNQ+] variant lost the prion in ~40% of the 
colonies (black bar), while medium [RNQ+] lost the prion in ~19% of the colonies (white 
bar), and strong [RNQ+] lost the prion in <1% of the colonies (grey bar).  (B) Full length 
endogenous Rnq1p in lysates from different [RNQ+] variants was fractionated by high 
speed centrifugation into total (T), supernatant (S), and pellet (P) fractions.  The amount 
of protein in the supernatant fraction decreased as the strength of the variant increased.  A 
representative blot from four independent experiments is shown. 
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Variants of [RNQ+] induce [PSI+] with different efficiencies- The only phenotype 
associated with the [RNQ+] prion state is its ability to induce the [PSI+] prion by acting as 
[PIN+].  While other protein aggregates can act as [PIN+], to date only [RNQ+] has been 
found commonly in lab and wild strains (34,53,54) and as such, is likely the most 
common, naturally occurring [PIN+] element.  Since we observed that [RNQ+] induced by 
protein transformation resulted in distinct variants based on nonsense suppression, we 
next wanted to test the ability of the variants to act as [PIN+] and induce [PSI+] (24,37).  
Red [psi-] [RNQ+] cells that were propagating different variants of the [RNQ+] prion were 
obtained by mating and sporulation as described in the previous section.  The progeny 
that expressed wild type SUP35 and did not have the RRP reporter were transformed with 
a plasmid expressing a second copy of SUP35 from its own promoter to induce [PSI+].  
Transformants were grown in selective media overnight to allow for Sup35p over-
expression and then plated on YPD.  The efficiency of [PSI+] induction was determined 
by counting the number of colonies with light pink sectors and dividing that by the total 
number of colonies.  In the [rnq-] controls, we did not observe any induction of the [PSI+] 
prion when SUP35 was over-expressed in the cell, while in [RNQ+] cells we obtained 
efficient induction of [PSI+] (Fig. 6).  As expected, the strong [RNQ+] variants showed a 
high level of induction of [PSI+], with > 60% of the colonies sectoring (Fig. 6).  The 
medium [RNQ+] variants had lower induction of [PSI+] when compared to strong [RNQ+].  
Surprisingly, the weak [RNQ+] variants demonstrated high levels of [PSI+] induction (Fig. 
6) that were comparable to the strong variants of [RNQ+].  Interestingly, the induction of 
[PSI+] we observed with our strong and weak [RNQ+] variants were reminiscent of the  
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FIGURE 6.  The [PSI+] induction capacity of the [RNQ+] variants is distinct.  
The over expression of Sup35p in the control [RNQ+] strain induced [PSI+] in ~62% of 
the colonies.  [PSI+] was not induced in [rnq-] cells.  Over expression of Sup35p in weak 
[RNQ+] variants induced [PSI+] in ~72% of the colonies, medium [RNQ+] variants 
induced [PSI+] in ~25% of the colonies, and strong [RNQ+] variants induced [PSI+] in 
~65% of the colonies. 
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previously characterized high and very high [PIN+] variants, respectively, that were 
previously published (38) and reconfirmed (data not shown).  
DISCUSSION 
The mechanism underlying the generation of prion variants was extensively 
investigated for only one yeast prion protein previously.  Both the physical and structural 
basis for variant formation of the [PSI+] prion from Sup35NM has been elucidated 
(25,26,29).  Here, we created and characterized different variants of the [RNQ+] prion.  
We assayed for prion variants in vivo using the chimeric protein RRP (40) that displayed 
distinct nonsense suppression phenotypes.  We used changes in temperature as a means to 
generate different amyloid structures and correlated those to prion variant formation in 
vitro and in vivo.  Rnq1PFD fibers formed at 18○C, 25○C, and 37○C have distinct 
biochemical and morphological properties.  Interestingly, fibers formed at 37○C have a 
shorter lag phase when compared to the 25○C fibers.  As expected, the stability of the 
fibers increased with the temperature at which the fibers were formed, which was also 
reflected by the morphology of the fibers observed by TEM.  We speculate that the fibers 
formed at 18○C are the least stable because they are short.  Fibers formed at 37○C appear 
to be the most stable and this may be due, in part, to the interactions between fibers.  The 
more stable 37○C fibers also show reduced seeding capacity as compared to fibers formed 
at 25○C.  The ability of 37○C Rnq1PFD fibers to seed new reactions was not enhanced by 
increased shearing, however (data not shown).  Finally, fibers formed at 18○C, 25○C, or 
37○C were transformed into [rnq-] yeast cells and each resulted in distinct distributions of 
[RNQ+] prion variants.   
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The correlation we observed between the length of the lag phase and the resulting 
[RNQ+] prion variants, however, was not in accordance with previously observed 
properties of Sup35NM fibers and [PSI+] variants.  In the case of Sup35NM, fibers 
formed at 25○C have a longer lag phase when compared to 4○C fibers (55).  When 
Sup35NM fibers are transformed into cells, strong [PSI+] variants are generated from 
fibers with a short lag phase and weak [PSI+] variants result from fibers that formed with 
a longer lag phase.  In stark contrast, although Rnq1PFD fibers formed faster at 37○C, 
they induced weaker [RNQ+] variants.  Rnq1PFD fibers formed slower at 25○C and 
induced strong [RNQ+] variants.  We would like to note that unlike Sup35NM, Rnq1PFD 
was unable to form discernable amyloid fibers at 4○C (data not shown).   
The correlation between the stability of Rnq1PFD amyloid fibers and the resulting 
prion variant distribution is similar to what was observed with Sup35NM and the [PSI+] 
prion (47).  We observed that an increase in the stability of the Rnq1PFD fibers 
correlated to an increase in weak [RNQ+] variants and a decrease in strong [RNQ+] 
variants.  From this, we suggest that the stability of the fibers is a critical property in 
determining the previously proposed parameters that dictate prion variants.  Since the rate 
of aggregation does not always correlate to the generation of specific prion variants, we 
suggest that this in vitro property cannot be generalized to determine the physical basis of 
variants in vivo.  As the addition of new protein occurs at fiber ends (30), it follows that 
the most efficient propagation requires more free ends for templating.  Faster 
aggregation, but slower disaggregation, would be unlikely to create strong variants, as is 
the case with Rnq1PFD fibers formed at 37○C.  However, fast “disaggregation” or 
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shearing could compensate for some reduction in the rate of aggregation, as is the case 
with Rnq1PFD fibers formed at 25○C.  
We were also able to determine the differences in the mitotic stability of the 
different [RNQ+] variants using the convenient RRP marker.  The ability to maintain the 
[RNQ+] prion state was intimately linked to the strength of the prion, with strong [RNQ+] 
being more stable than medium [RNQ+], and medium [RNQ+] being more stable than 
weak [RNQ+].  The stability of the different variants could be related to the ratio of 
aggregated to soluble protein, the size of the aggregates, and the ability of Hsp104p and 
other chaperones to generate seeds that can be passed on to daughter cells.   
We further characterized the [RNQ+] variants by assaying their ability to act as 
[PIN+] and induce [PSI+].  Surprisingly, both weak [RNQ+] and strong [RNQ+] induced 
[PSI+] at high efficiencies (> 60%) when compared to the medium [RNQ+] variant.  
Interestingly, the weak [RNQ+] variant was denoted as weak based on solubility of Rnq1p 
and low levels of nonsense suppression using RRP, but it maintained the greatest capacity 
to induce [PSI+].  We compared our variant to the previously described variants of the 
[RNQ+] prion that were obtained spontaneously (38).  They were classified based on their 
ability to induce [PSI+] into low, medium, high, and very high [PIN+] variants.  The 
extent of aggregation of Rnq1p correlated to an increase in [PSI+] induction efficiency 
with the low, medium, and high variants.  However, the very high [PIN+] variant did not 
fit the trend as it showed the largest amount of soluble Rnq1p, but had the greatest 
capacity to induce [PSI+].  Therefore, we propose that the weak [RNQ+] variants we 
obtained by protein transformation are most similar to the previously obtained very high 
[PIN+] variant (38).  Since the RRP phenotype likely reflects co-aggregation with wild 
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type Rnq1p in the [RNQ+] state and the induction of [PSI+] likely reflects some transient 
physical interaction with Sup35p (40,56), we suggest that very high [PIN+]/ weak [RNQ+] 
forms a structure that affords less efficient self-templating but more efficient interaction 
with Sup35p than other variants.  While the medium and strong [RNQ+] variants 
correspond to medium and high [PIN+], we note one important caveat in the 
interpretation of the differences in the ability to induce [PSI+].  The reduced [PSI+] 
induction we observed with medium [RNQ+] is probably due in part to the decreased 
mitotic stability of medium [RNQ+] when compared to high [RNQ+].  This is not likely to 
explain the differences entirely, however, as different structures of Rnq1p in [RNQ+] are 
likely to interact differently with Sup35p to induce [PSI+]. 
Here, we have defined conditions for the aggregation of Rnq1PFD in vitro that 
result in the induction and propagation of specific [RNQ+] variants in vivo.  These data 
are consistent with a direct relationship between the biochemical properties of amyloid 
fibers and prion variants.  The information gleaned from the generation of [RNQ+] prion 
variants suggests that there may be some general properties dictating prion strain 
propagation, while others are unique to individual prion proteins.  Using the [RNQ+] 
variants and the ability to investigate their in vitro properties, we may be able to delineate 
the mechanisms involved in the self-seeding of Rnq1p to maintain variants of [RNQ+] 
from those involved in cross-seeding Sup35p to induce [PSI+].  Hence, this provides a 
tractable system to investigate mechanisms that impact protein aggregation and the onset 
of protein conformational disorders. 
EXPERIMENTAL PROCEDURES 
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Protein purification- The pHis10-Rnq1PD (amino acids 132-405) construct (39) 
was transformed into Escherichia coli BL21(DE3) cells.  Resultant transformants were 
scraped to inoculate large cultures in CircleGrow media and the cells were grown to an 
OD600~0.6.  The expression of Rnq1PFD was induced with 1 mM IPTG for 6 hrs.  The 
cells were harvested and incubated with agitation at room temperature for one hour in 20 
mM Tris-HCl, 8 M Urea (Buffer A, pH 8).  The cells were then further lysed by 
sonication.  The lysate was cleared by spinning at 10,000 x g for 30 minutes.  The 
supernatant was incubated with Ni2+-Sepharose beads for two hours.  Subsequently, the 
beads were packed in a column and washed with 25 column volumes (CV) Buffer A, pH 
8.  The beads were then washed successively with four CV each of Buffer A, pH 6.3 and 
Buffer A, pH 5.9, before eluting with Buffer A, pH 4.5.  Rnq1p in the eluted fractions 
was verified for purity by SDS-PAGE and coomassie staining.  The fractions containing 
the protein were filtered through a 100kD molecular weight cut off column (Amicon) and 
stored in methanol at -80○C.  
Amyloid fiber formation- Kinetic assays of fiber formation were done in a 
SpectraMax M2e flourimeter microplate reader.  Rnq1PFD fibers were diluted 75-fold 
from 7 M guanidine hydrochloride to a concentration of 4 µM in FFB buffer (150 mM 
NaCl, 5 mM KPO4, 2 M Urea, pH 7.4) with 50-fold molar excess Thioflavin-T to initiate 
fiber formation in the presence of glass beads for agitation.  The change in Thioflavin-T 
fluorescence over time was measured using an excitation wavelength of 450 nm and 
emission wavelength of 481 nm.  The plate was agitated each minute prior to reading for 
ten seconds.  Fibers were also formed in a rotator (end-over-end) at a monomer 
 98
concentration of 4 µM for thermostability assays and to obtain seeds for seeding 
experiments.  For the seeded experiments, the fibers were seeded using 5% (w/w) seed.   
Thermostability assay- Pre-formed fibers were treated with 2% SDS for five 
minutes at different temperatures (gradient from 55○C to 95○C, with 5-7○C increments).  
The treated samples were analyzed by SDS-PAGE and western blot using an anti-Rnq1p 
antibody.  The bands were quantified using ImageJ software and values were normalized 
to the 95○C band.  Results were plotted using Origin 6.1 statistical software. 
 Electron microscopy- Samples of fibrillar Rnq1PFD were allowed to settle onto 
freshly glow-discharged 200 mesh carbon-formvar coated copper grids for 10 minutes.  
Grids were then rinsed twice with water and stained with 1% uranyl acetate (Ted Pella) 
for one minute.  Samples were viewed on a JEOL 1200EX transmission electron 
microscope (JEOL USA).  Protein transformation-  Transformation of Rnq1PFD 
fibers into a [rnq-] 74-D694 (ade1-14, ura3-52, leu2-3,112, trp1-289, his3-200, 
sup35::RRP) yeast strain was conducted as described (44).  The resulting colonies were 
replica plated onto rich media (YPD) plates to assay for colony color.  Colonies that 
appeared to have acquired the prion state by nonsense suppression were picked and 
spotted on YPD, YPD containing 3 mM GdnHCl and SD-ade for phenotypic analyses.   
Mitotic Stability of [RNQ+]- Three independent protein transformants for each of 
the [RNQ+] prion variants were grown in liquid YPD media overnight (~16 hours) to an 
OD600 of ~2.0.  The cultures were diluted 8,000-fold in water and 250 µl were plated on 
13 cm (diameter) YPD plates.  Approximately 750 colonies for each transformant and a 
total of > 2,000 colonies were counted for each variant. The average and standard 
deviation is reported for each variant. The percentage of cells that lost the prion was 
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calculated by dividing the number of red cells by the total number of cells.  The loss of 
the [RNQ+] prion was confirmed by Rnq1p solubility assays for 10 representative 
colonies of each variant.  
[PSI+] induction assay- Yeast strains containing the [RNQ+] prion were 
transformed with pEMBL-SUP2 (41) and plated on SD-ura.  Transformants were grown 
in selective media to an OD600 of ~1.6 and plated on YPD.  After 5 days of growth, [PSI+] 
cells were counted as any cell with a light pink sector.  Representative colonies were 
checked for curing by transient growth on media containing 3 mM GdnHCl. 
 [RNQ+] solubility assay-  The protocol was adapted from previously published 
work (34). The yeast cells were lysed in buffer containing 100 mM Tris-HCl, pH 7, 200 
mM NaCl, 1 mM ethylendiaminetetraacetic acid (EDTA), 5% glycerol, 0.5% 
dithiothreitol (DTT), 50 mM N-ethyl malemide (NEM), 3 mM 
phenylmethanesulphonylfluoride, and EDTA-free complete Mini protease inhibitor 
cocktail (Roche).  Lysis was performed by vortexing with glass beads.  Following lysis, 
an equal volume of RIPA buffer (50 mM Tris-HCl, pH 7, 200 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, and 0.1% SDS) was added to the lysate and cell debris 
was cleared by centrifugation at 3,300 x g for 15 seconds.  A portion of this cleared lysate 
was saved for the total protein sample.  Aggregated protein was pelleted by centrifugation 
at 80,000 rpm in a Beckman TLA-100 rotor for 30 min. The supernatant containing the 
soluble protein was removed and the pellet was resuspended in a 1:1 mix of lysis buffer 
and RIPA buffer.  The total, supernatant, and pellet fractions were subjected to SDS-
PAGE, transferred to PVDF membrane, and probed with an anti-Rnq1p antibody. 
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SUMMARY 
Prion diseases are unique neurodegenerative disorders that are transmitted by a 
misfolded and aggregated form of and endogenously expressed protein.  Many lines 
of evidence suggest that the misfolded and aggregated forms of prion protein (PrP) 
form the infectious particles.  Amyloid fibers formed by PrP share many of their 
biochemical and structural properties with fibers formed by other proteins that 
cause protein conformational disorders.  However, the other proteins such as α-
synuclein and amyloid-β, although capable of causing disease, do not appear to be 
infectious.  The properties that confer infectivity to protein aggregates such that 
they act as “prions” are unclear, and this represents a major question.  Yeast also 
harbor prions.  One is termed [RNQ+], formed by aggregation of Rnq1p.  In this 
study, we have used a deletion mutant in the prion-forming domain (PFD), of 
Rnq1p (Rnq1PFD, amino acids 133-405) termed Rnq1PFD∆Hot (deletion of amino 
acids 284-317) to dissect biochemical and structural properties of infectious versus 
non-infectious amyloid.  Rnq1PFD∆Hot forms amyloid fibers at both 25○C and 
37○C, as assayed by Thioflavin-T (Th-T) binding and transmission electron 
microscopy (TEM).  These fibers also resist thermal denaturation.  However, when 
the fibers are transformed into yeast cells, those formed at 37○C are infectious, 
whereas fibers formed at 25○C are not.  We suggest that a conformational change 
caused by the assembly of the fibers formed at the two distinct temperatures is 
responsible for the change in the ability of the protein aggregates to be infectious.  
Biophysical experiments are currently underway to identify these structural 
differences between the infectious and non-infectious Rnq1PFD∆Hot fibers.  
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 Protein misfolding and aggregation has been associated with several diseases that 
affect many mammals including humans (1).  Neurodegenerative diseases form a major 
subset of these protein conformational disorders (2).  Most often, these diseases occur 
sporadically, but they can also be caused by mutations in the gene(s) associated with the 
disease (1).  A common feature of neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s and Huntington’s is the deposition of amyloid fibers in the brain (3).  Prion 
diseases are a unique class of neurodegenerative diseases in that they are also 
transmissible or infectious (4).  The misfolded and aggregated material found in 
extracellular deposits in individuals affected with prion disease primarily consist of PrP 
aggregates (5).  These aggregates are thought to be the agents of infection.  It is not 
entirely clear if all protein aggregates are infectious or if there are certain special 
characteristics that allow PrP aggregates to become infectious.  
 Interestingly, many of the proteins or peptides implicated in neurodegenerative 
diseases such as amyloid-β (in Alzheimer’s), α-synuclein (in Parkinson’s), repeat 
expanded huntingtin exon-1 (in Huntington’s), and PrP (Prion diseases) share many 
biochemical properties.  They can all form amyloid fibers in vitro.  Furthermore, they all 
seem to follow a similar kinetic pattern when converting from a denatured monomer to 
amyloid fiber with an initial lag phase, followed by an exponential growth phase and a 
final plateau phase (6,7).  Additionally, “seeds” obtained from previously formed fibers, 
greatly enhance the conversion of protein monomers into fibers and either reduce or 
completely eliminate the lag phase, suggesting a nucleated conformational conversion 
model for polymerization (6,7).  The ability of “seeds” to template polymerization in 
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vitro suggests that introduction of the misfolded conformation in organisms via 
transmission or infection may provide a means for onset and propagation of disease.   
However, the only known cases of human epidemics involving amyloidogenic 
proteins are with PrP aggregates.  Ritualistic cannibalism in the Fore tribe of Papua New 
Guinea and the cross-species transmission of bovine spongiform encephalopathy (BSE) 
into humans to cause variant Cruetzfeld-Jacob disease (vCJD) are two well-documented 
cases of transmission of disease by protein aggregates (8,9).  There is new evidence 
however in model systems that suggests that other protein conformational disorders may 
also have the capacity to infect and propagate in a manner similar to prion diseases.  
The most compelling case for infectivity of another disease that has prion-like 
features can be made for AA amyloidosis (10).  However, in the disease model, the 
recipient mouse needs to be primed, for example by injecting silver nitrate, for elevated 
levels of serum Amyloid A in order for disease to be acquired by introduction of 
aggregated Amyloid A into the mouse (10).  Additionally, there is evidence to suggest 
that transgenic mice used as an Alzheimer’s disease model also accumulate plaques at an 
earlier time if injected with brain homogenate from mice with amyloid-β plaques (11).  
Furthermore, experiments in cell culture show that protein aggregates introduced into the 
culture media, can be taken up by the cell, thus providing a potential means for 
propagation of disease (12,13).  
It is, important to note however, that there are many issues that need to be 
considered before a disease can truly be considered to transmit via a prion-like 
mechanism.  These issues include temporal and topological pattern of expression of the 
protein and localization of the protein in a cell.  We suggest that, in addition to the 
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specific requirements mentioned above, there are structural and biochemical features that 
permit a protein to become infectious.  Important factors to consider when determining 
the ability of a protein to be infectious include 1) the ability of a misfolded protein to 
faithfully template the conversion of monomer into a specific conformation and then 
aggregate and 2) the ability of the protein aggregates to disaggregate to further template 
conversion.  
In this study, we have made use of a mutant form of the yeast prion protein Rnq1p 
that can form amyloid fibers that are both infectious and non-infectious.  The Rnq1 
protein has no known function in its soluble state, but when it aggregates to form the 
[RNQ+] prion, it enhances the induction another yeast prion, called [PSI+] (14,15).  The 
PFD of Rnq1p extends from amino acids 153-405.  The mutant form of Rnq1PFD we 
used contains a deletion of the amino acids 284-317 (Rnq1PFD∆Hot) (16-19).   
This deletion mutant was previously generated in our lab while determining 
regions of Rnq1p that were important for the maintenance of the [RNQ+] prion (16).  In 
this study (16), a PCR mutagenesis of the PFD of RNQ1 was conducted to identify 
mutants that failed to propagate the [RNQ+] prion.  A significantly larger number of 
mutants that were identified fell between amino acids 284-317.  Therefore, this region, 
identified as a hotspot for mutants in RNQ1 PFD that failed to propagate the [RNQ+] 
prion was deleted (Rnq1∆Hot) to further investigate its role in prion propagation.  The 
Rnq1∆Hot mutant was able to propagate low and medium variants of [RNQ+].  It was 
however unable to propagate the high [RNQ+] variant.  
We show that Rnq1PFD∆Hot can form amyloid fibers in vitro with typical 
kinetics as observed by Th-T assay at both 25○C and 37○C.  Seeds obtained from fibers 
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formed at either temperature were able to substantially enhance the polymerization of 
monomeric protein.  We were able to identify subtle differences in morphology, in the 
fibers at the two temperatures by TEM.  Fibers formed at both temperatures were 
resistant to thermal denaturation.  However, when the fibers were transformed into [rnq-] 
yeast cells, only fibers formed at 37○C were able to induce the [RNQ+] prion state. Fibers 
formed at 25○C were unable to infect the cells and induce the prion state.  We suggest 
that the Rnq1pPFD∆Hot fibers formed at 25○C have acquired a conformation that is 
unable to infect yeast and propagate the [RNQ+] prion.  In contrast, 37○C fibers have a 
conformation that is infectious.  We propose that this model could be used to obtain 
structural signatures that may represent the ability of a protein aggregate to be infectious 
or benign.  
RESULTS 
 Temperature has a profound impact on the kinetics of Rnq1PFD∆Hot 
fiber formation- We purified recombinant Rnq1PFD∆Hot in 8 M Urea as described in 
experimental procedures.  The purified Rnq1PFD∆Hot protein formed amyloid fibers 
when diluted out of denaturant.  The length of the lag phase of fiber formation is a 
parameter that can be used to measure the ability of the protein to aggregate and is a 
difference commonly found between amyloid fibers of different morphologies; a longer 
lag phase indicates a reduced ability to aggregate.  We used different temperatures to 
generate structural variation in the fibers of Rnq1PFD∆Hot.  We followed fiber formation 
of Rnq1PFD∆Hot at 25○C and 37○C using a Thioflavin-T fluorescence assay.  At 25○C, 
Rnq1PFD∆Hot fibers had a lag phase of ~450 minutes followed by a logarithmic growth  
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FIGURE 1.  Fiber formation of Rnq1PFD∆Hot is faster at higher temperatures and 
enhanced by the addition of pre-formed seeds.  Purified Rnq1PFD∆Hot was diluted 
from denaturant (75-fold) to 4 µM and fiber formation was followed using Th-T 
fluorescence.  Graphs are plotted as %RFU (relative fluorescence units) versus time.  (A) 
Rnq1PFD∆Hot unseeded at 25○C (black) and seeded with 5% seeds (red).  (B) 
Rnq1PFD∆Hot fiber formation at 37○C unseeded (black), and with 5% seeds (red).  
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phase (Fig. 1A).  In contrast, fiber formation of Rnq1PFD∆Hot at 37○C had a shorter lag 
phase of ~200 minutes (Fig. 1B).   
The ability of seeds to enhance the conversion of monomeric protein into fibers is an 
important feature of nucleated conformational conversion for amyloid fiber formation 
(7,20).  We formed Rnq1PFD∆Hot fibers at 25○C and 37○C and tested the ability of the 
fibers to act as seeds and template the addition of freshly diluted monomeric 
Rnq1PFD∆Hot.  The seeds obtained from fibers formed at 25○C, as well as those formed 
at 37○C, were capable of templating new fiber formation at 25○C and 37○C, respectively 
(Fig. 1A and 1B).   
 Rnq1PFD∆Hot fibers formed at 37○C infect yeast cells to induce the [RNQ+] 
prion but those formed at 25○C are not infectious- The prion hypothesis suggests that 
when purified recombinant prion protein is made to aggregate in vitro and introduced into 
an organism the aggregates should infect the organism and propagate.  Only very recently 
infectious material from a recombinant source for PrP has been shown to fulfill this 
hypothesis (21).  However, significant advancement to provide this ultimate proof for the 
“prion hypothesis” hypothesis was facilitated by the study of fungal prions.  HET-s a 
prion protein of the fungus Podospora anserina, Sup35p, Ure2p and Rnq1p, both prions 
of the yeast S. cerevisiae have been shown to produce infectious prion particles when 
purified recombinant protein is assembled in vitro to form amyloid fibers (17,22-24).  
 Here we used a yeast strain that expressed the [RNQ+] reporter protein 
(RRP) to assay infectivity of amyloid fibers formed by Rnq1PFD∆Hot (16,18).  The RRP 
is a fusion of amino acids 133-405 from Rnq1p to the N-terminus of the middle and C-
terminal domain Sup35p (amino acids 124-685).  Sup35p is the eukaryotic release factor  
 113
   
 
 
 
 
Table 1. Ability of Rnq1PFD∆Hot to infect yeast. Yeast colonies that resulted from 
infection of Rnq1PFD∆Hot fibers formed at  25○C, and 37○C were grouped into weak, 
medium, and strong [RNQ+] strains based on RRP-mediated colony color (on YPD) and 
growth on medium lacking adenine (SD-ade).  The numbers in the table reflect the 
percentage of variants obtained by infectivity assays after counting over 3,000 
transformed colonies for infection of fibers formed at 25○C and 300 colonies for 37○C 
fibers from more than three experiments for 37○C and 10 experiments for 25○C fibers. 
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3 and is important for translation termination at stop codons.  The RRP fusion protein 
reports on the prion status of Rnq1p.  The RRP presumably co-aggregates with Rnq1p in 
the [RNQ+] state and allows for readthrough of premature stop codons in the aggregated 
state.  The allele ade1-14, contains a premature stop codon.  Increased read through of 
stop codons (as would be the case in [RNQ+] cells) turns cells white and faithful 
termination turns cells red in color.  Therefore, we were able to use a red/white colony 
color assay to determine the prion status of Rnq1p in cells.   
We transformed yeast cells with amyloid fibers formed in potassium phosphate buffer, 
pH 7.4, 150 mM sodium chloride and 2 M urea, with end-over-end agitation, with 
Rnq1PFD∆Hot at 25○C and 37○C and assayed for the induction of [RNQ+].  We have 
identified Rnq1PFD∆Hot as a protein that is presumably capable of infecting in one 
conformation and not another.  As shown in Table 1, fibers of Rnq1PFD∆Hot formed at 
37○C infect cells and induce weak and medium variants of the [RNQ+] prion, but when 
fibers are formed at 25○C, they cannot infect yeast cells to induce [RNQ+]. 
Rnq1PFD∆Hot fibers formed at different temperatures are differentially stable- 
The stability of the amyloid fibers has proven to be predictive of prion variants they 
induce when transformed into yeast.  More stable amyloid fibers have a longer core and 
propagate weaker prion variants while less stable fibers with a shorter core propagate 
stronger prion variants (25-27).   
We next asked if the stability of the infectious amyloid fibers of Rnq1PFD∆Hot 
differed from those that were not able to induce the [RNQ+] prion.  We used 
thermostability to determine the relative stability of Rnq1PFD∆Hot fibers formed at 
different temperatures.  We formed fibers at 18○C, 25○C, and 37○C and subjected them to  
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FIGURE 2.  Rnq1PFD∆Hot fibers formed at higher temperatures are more stable.  
Preformed fibers were treated across a temperature gradient in the presence of 2% SDS.  
Following SDS-PAGE and western blot, the amount of soluble Rnq1PFD∆Hot was 
quantified and the results were graphed as a percentage of total protein at 95○C using 
OriginPro 6.1 with a sigmoidal fit function. 
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FIGURE 3.  The morphology of amyloid fibers formed from Rnq1PFD∆Hot at 
different temperatures shows subtle changes.  Amyloid fibers of Rnq1PFD∆Hot 
formed in vitro were imaged by TEM.  The scale bar represents 200 nm. (A) 18○C fibers 
are short and thin (B) 25○C fibers are short and thin, and (C) 37○C fibers are lwider. 
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increasing temperatures in 2% SDS.  We then analyzed the soluble protein by SDS-
PAGE and western blot.   We found that fibers formed at 18○C and 25○C were more 
labile and showed ~50% disruption at 71○C (Fig. 2).  Fibers formed at 37○C were 
significantly more stable and showed ~50% dissociation at 81○C.  Thus, the stronger 
amyloid fibers formed at 37○C yield amyloid fibers that were able to infect yeast and the 
benign fibers that were formed at 25○C were weaker.  
Transmission electron microscopy (TEM) reveals subtle morphological differences in 
Rnq1PFD∆Hot fibers- The observed differences in kinetics and stability of amyloid 
fibers of Rnq1PFD∆Hot formed at different temperatures and their ability to infect yeast 
cells to induce the [RNQ+] prion led us to hypothesize that the morphology of the 
Rnq1PFD∆Hot fibers formed at these temperatures may be distinct.  In order to 
determine if there were any morphological differences between the Rnq1PFD∆Hot fibers 
formed at 18○C, 25○C, and 37○C we obtained TEM images of these amyloid fibers.  In 
fact, we did observe subtle differences in the morphology of the fibers formed at the 
different temperatures.  Rnq1PFD∆Hot fibers formed at 18○C, 25○C and 37○C are all 
short (Figure 3).  There appeared to be subtle changes in the width of the amyloid fibers 
formed at each of these temperatures however. Fibers formed at 37○C appeared slightly 
thicker than those formed at 18○C and 25○C.  . 
DISCUSSION 
 The hypothesis that an infectious agent may contain only protein and no nucleic 
acid was received with much skepticism initially (4).  However, since then, there has 
been considerable evidence in mammalian systems (4,21) and compelling evidence in 
fungal prion systems to suggest that protein infectious particles or “prions” to prove this 
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hypothesis true (27).  However, considering that there are other proteins that are 
implicated in disease such as the amyloid-β peptide, α-synuclein and Huntington exon 1 
share many biochemical and structural characteristics that are similar to PrP and prion 
disease, it has been proposed that these proteins too, given the opportunity, may be 
infectious (12,28).  There is some evidence to suggest that many of the protein misfolding 
and aggregation diseases may have prion-like properties.  However, to date, only prion 
disease caused by PrP protein aggregates has been shown to be capable of being truly 
infectious.  
 Here, we have identified a unique protein fragment, Rnq1PFD∆Hot that can form 
amyloid fibers that capable of forming both infectious amyloids and those that are not.  
We were able to modify the infectivity of the Rnq1PFD∆Hot fibers by changing the 
temperature of assembly.  Rnq1PFD∆Hot fibers formed faster at 37○C as compared to 
25○C.  Furthermore, fibers formed at both temperatures were able to act as seeds and 
enhance polymerization of monomeric Rnq1PFD∆Hot protein.  Surprisingly, however, 
when Rnq1PFD∆Hot fibers formed at 25○C were transformed into yeast cells, they did 
not infect cells.  The fibers formed at 37○C, in contrast, were capable of infecting cells.  
The 37○C Rnq1PFD∆Hot fibers induced medium and weak variants of the [RNQ+] prion.  
Interestingly, Rnq1∆Hot protein (Full length Rnq1p with amino acids 284-317 deleted) 
does not maintain high [RNQ+] in vivo either.  Therefore the fibers formed in vitro 
presumably acquire conformations that appear to be pertinent to the in vivo aggregate 
structure.  We characterized the thermal stability of the amyloid fibers formed at different 
temperatures and found that 37○C fibers were more stable than those formed at either 
25○C or 18○C .  Finally, in sharp contrast to the differences in the ability of the fibers to 
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infect yeast cells, we found that the fibers had similar morphologies, as visualized by 
TEM.   
We suggest that changes in the intra- and inter-molecular contacts made during 
fiber assembly cause significant differences that result in their differential ability to infect 
yeast cells.  These changes in contacts may not result in supra-molecular changes to the 
morphology of the fibers, but may change other biochemical properties and finer 
structural properties.  We propose to use the Rnq1PFD∆Hot model polypeptide to 
identify structural features that correlate infectious versus non-infectious protein 
aggregates.  
One possible explanation for the ability of a specific protein to form infectious or 
non-infectious aggregates, is based on the ability to propagate as different “prion strains”.  
For a protein to be infectious, not only does it need to be capable of efficiently 
aggregating, but it also needs to be able to faithfully convert soluble species or other 
monomers to an aggregated state.  Furthermore, once the aggregates are formed, they 
need to be sheared in order to increase the number of sites for the templating reaction to 
occur efficiently.  The ability to shear an aggregate and increase the number of sites for 
propagation of the amyloid conformation is presumably as crucial as the initial structural 
conversion.  Therefore, we suggest that protein aggregates that not transmissible are 
conformations that form very unstable variants.  
 The unstable variant conformations of yeast prions are inefficient at transmitting 
“seeds” from mother cell to daughter cells (29).  Rnq1PFD∆Hot fibers formed at 25○C 
may be in a conformation that is unstable in vivo because the templating is inefficient.  
Additionally, the 25○C Rnq1PFD∆Hot fibers are also fairly stable and this may prevent 
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the shearing of aggregated protein in vivo and decrease the number of templating sites 
and transmissible seeds.  In combination, this may create a situation in vivo that results in 
unstable propagation of the prion state, resulting in rapid loss of the prion state altogether.  
On the other hand, the conformation of the fibers formed at 37○C produce weaker 
variants that are more stable in vivo because the fibers are more efficient at aggregating 
as compared to 25○C fibers.  Although this conformation is more stable, the efficiency of 
aggregation may compensate for the potential reduction in shearing of the aggregated 
protein.  
Other models to explain the lack of infectivity by Rnq1PFD∆Hot fibers formed at 
25○C include the possibility that this conformation is in fact an extremely strong variant 
of [RNQ+].  The high rate of aggregation in the strong variant may render the chaperone 
machinery inefficient to disaggregate the protein.  It is also possible that the specific 
conformation adapted at 25○C is either not recognized at all by the chaperone machinery, 
hence, preventing the generation of seeds. Alternatively the chaperones may be very 
efficient at clearing the aggregates formed at 25○C and prevent aggregation altogether. 
We suggest that the difference in the ability of the amyloid fibers formed at 37○C 
to infect and 25○C to not infect cells is due to conformational changes in the monomer 
when it forms the amyloid fibers at the two different temperatures. We propose future 
work using biophysical techniques to identify these structural changes.  Understanding 
the specific interactions of amino acids in the two different conformations may provide 
clues toward understanding properties that make certain protein aggregates infectious and 
others benign.   
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Here, we have defined conditions for the aggregation of Rnq1PFD∆Hot in vitro 
that yeild two different conformations of amyloid fibers, one that is infectious and 
another that is not.  The data obtained here is consistent with a hypothesis that proposes 
direct relationship between the biochemical and structural properties of amyloid fibers 
and their ability to be infectious.  The information gleaned from the infection of yeast 
cells to induce the prion state suggests that there we may be able to identify some general 
properties that dictate infectivity of amyloid fibers.  Using the different conformations of 
Rnq1PFD∆Hot to investigate their in vitro properties, we may be able to delineate the 
mechanisms and structural features necessary for infectivity. Thus [RNQ+] yeast prion 
system provides a tractable system to investigate a major, controversial and highly 
debated question in the field of protein misfolding and aggregation. 
EXPERIMENTAL PROCEDURES 
Protein purification- The pHis10-Rnq1PFD∆Hot construct was transformed into 
Escherichia coli BL21 (DE3) cells.  The resulting transformants were scraped and used to 
inoculate large cultures in CircleGrow media. The cells were grown to an OD600~0.6.  
The expression of Rnq1PFD∆Hot was induced with 1 mM IPTG for 6 hrs.  The cells 
were harvested and incubated with agitation at room temperature for one hour in 20 mM 
Tris-HCl, 8 M Urea (Buffer A, pH 8) and lysed by sonication.  The lysate was cleared by 
spinning at 10,000 x g for 30 minutes.  The supernatant was incubated with Ni2+-
Sepharose beads for two hours.  Subsequently, the beads were packed in a column and 
washed with 25 column volumes (CV) Buffer A, pH 8.  The beads were then washed 
successively with four CV each of Buffer A, pH 6.3 and Buffer A, pH 5.9, before eluting 
with Buffer A, pH 4.5.  Rnq1PFD∆Hot in the eluted fractions was verified for purity by 
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SDS-PAGE and coomassie staining.  The fractions containing the protein were filtered 
through a 100kD molecular weight cut off column (Amicon) and stored in methanol at -
80○C.  
Amyloid fiber formation- Kinetic assays of fiber formation were done in a 
SpectraMax M2e fluorimeter microplate reader.  Rnq1PFD∆Hot fibers were diluted 75-
fold from 7 M guanidine hydrochloride to a concentration of 4 µM in FFB buffer (150 
mM NaCl, 5 mM KPO4, 2 M Urea, pH 7.4) with 50-fold molar excess Thioflavin-T to 
initiate fiber formation in the presence of glass beads for agitation.  The change in 
Thioflavin-T fluorescence over time was measured using an excitation wavelength of 450 
nm and emission wavelength of 481 nm.  The plate was agitated each minute prior to 
reading for ten seconds.  Fibers were also formed in a rotator (end-over-end) at a 
monomer concentration of 4 µM for thermostability assays and to obtain seeds for 
seeding experiments and for protein transformation experiments.  For the seeded 
experiments, the fibers were seeded using 5% (w/w) seed.   
Thermostability assay- Pre-formed fibers were treated with 2% SDS for five 
minutes at different temperatures (gradient from 55○C to 95○C, with 5-7○C increments).  
The treated samples were analyzed by SDS-PAGE and western blot using an anti-Rnq1p 
antibody.  The bands were quantified using ImageJ software and values were normalized 
to the 95○C band.  Results were plotted using Origin 6.1 statistical software.   
Electron microscopy- Samples of fibrillar Rnq1PFD∆Hot were allowed to settle 
onto freshly glow-discharged 200 mesh carbon-formvar coated copper grids for 10 
minutes.  Grids were then rinsed twice with water and stained with 1% uranyl acetate 
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(Ted Pella) for one minute.  Samples were viewed on a JEOL 1200EX transmission 
electron microscope (JEOL USA).   
Protein transformation- Transformation of Rnq1PFD∆Hot fibers into a [rnq-] 74-
D694 (ade1-14, ura3-52, leu2-3,112, trp1-289, his3-200, sup35::RRP) yeast strain was 
conducted as described.  The resulting colonies were replica plated onto rich media 
(YPD) plates to assay for colony color.  Colonies that appeared to have acquired the prion 
state by nonsense suppression were picked and spotted on YPD, YPD containing 3 mM 
GdnHCl and SD-ade for phenotypic analyses.   
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SUMMARY 
We have established an efficient assay to study the effect that a variety of different 
conditions have on amyloid fiber formation.  We have used Sup35NM and 
Rnq1PFD, the prion forming domains (PFD) of the yeast proteins Sup35p and 
Rnq1p respectively, as model amyloidogenic proteins.  Sup35p and Rnq1p 
aggregate in vivo to determine the yeast prions [PSI+] and [RNQ+] respectively and 
their PFDs have been shown to form amyloid fibers in vitro.  Fibers formed at 
physiological pH (7.4) differ in kinetics of assembly and stability depending on the 
presence of denaturant (urea), salt (NaCl), divalent cation (MgCl2), osmolyte 
(sorbitol), molecular crowding agent (polyethylene glycol, PEG) and viscous liquid 
(glycerol) in the solution.  The effect of the different conditions on the kinetics of 
fiber formation was profound and rather disparate for Sup35NM and Rnq1PFD.  
The stability of the fibers formed in different conditions was dramatically affected 
for Sup35NM but only subtly affected for Rnq1PFD fibers.  We are currently 
testing the ability of Sup35NM and Rnq1PFD fibers formed in the different 
conditions to induce [PSI+] and [RNQ+], respectively.  We are also in the process of 
analyzing the morphology of the fibers using transmission electron microscopy 
(TEM) and atomic force microscopy (AFM).  We hypothesize that variation in the 
structure of the amyloid fibers formed by Sup35NM and Rnq1PFD is a result of the 
interactions of the two proteins with the solvent conditions.   Based on our kinetic 
data, we suggest that the interaction of the polypeptide with the solvent is sequence -
dependent and that the same solvent conditions may have drastically different 
effects on different amyloidogenic polypeptides.  Fibrillar polymorphism has been 
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reported for many different proteins and may have various biological consequences 
including forming the basis for variation in disease pathology and transmissibility.    
 The amyloid fiber has been suggested to be a structure that most if not all, 
polypeptides and proteins can access if given the right conditions (1).  Deposition of 
amyloid fibers formed from a variety of proteins has been associated with many 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s and prion diseases (2-4).  
Amyloid fibers formed from various proteins and peptides have been used to obtain the 
molecular structure of these ordered aggregates.  Techniques such as solid state NMR and 
X-ray diffraction have provided breakthroughs towards obtaining an atomic resolution 
structure for amyloid fibers (5-8).  Furthermore, an atomic resolution model for the basis 
of structural variation and the resulting polymorphism in amyloid fibers has also been 
proposed (9).  Previous work done by our laboratory (Kalastavadi and True, JBC, In 
Revision) and others using yeast prion proteins as a model has provided evidence to link 
variation in the morphology and biochemical properties of the amyloid fibers to prion 
strain formation (10,11).  Work done by others on yeast prion strains (called variants in 
yeast) has also shown differences in inter- and intra-molecular contacts between 
monomers that form the fiber in different variants, hence suggesting a role for monomer-
monomer interactions in generating the structural polymorphisms observed with amyloid 
fibers (12,13).  Polymorphisms in amyloid fibers have also been observed in protein 
deposits found in protein misfolding diseases (14).  Although significant work has been 
done toward understanding the structural basis for the polymorphisms, not much is 
known about how different environmental conditions interact with different 
amyloidogenic proteins to create amyloid fiber polymorphism.  Recent studies have 
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reported the effect of solvent conditions on fiber morphology (15,16), but these systems 
lack the ability to assay the phenotypic consequences of the diverse morphologies and 
properties inside a cell. 
 In this study, we have used two different yeast prion proteins, Sup35NM and 
Rnq1PFD, to dissect the effect that solvent conditions have on amyloid fiber morphology 
and prion phenotype (for a review on yeast prions (17)).  Both Sup35NM and Rnq1PFD 
form amyloid fibers in vitro when diluted out of denaturant (18-20).  Sup35NM has been 
shown to form ordered amyloid fibers in a potassium phosphate buffer (5 mM at pH 7.4) 
containing 150 mM sodium chloride (FFB) (18).  Rnq1PFD has been shown to form 
amyloid fibers in the same buffer, but in the presence of 2 or 4 M urea (FFB + 2 M Urea) 
((21) and True and Kalastavadi, JBC, in revision).  We have investigated the effect of 
concentrations of denaturant (urea), salt (NaCl), divalent cation (MgCl2), osmotic stress 
(sorbitol), molecular crowding agent (PEG) and viscous agent (glycerol) on amyloid fiber 
formation of both Sup35NM and Rnq1PFD.  We found that solvent conditions 
dramatically affected the rate of fiber formation and stability for Sup35NM.  Rnq1PFD 
fiber formation kinetics was also influenced dramatically by the various solvent 
conditions, but the effect on stability was more subtle.  We propose to assay morphology 
of these fibers by EM and AFM, and differences in their secondary structure using 
thioflavin-T (Th-T) fluorescence spectra, CD, and FTIR spectra.  We are currently in the 
process of determining what prion variants are induced by Sup35NM and Rnq1PFD 
fibers formed in the different solvent conditions.  Our preliminary results suggest that 
solvent conditions do not uniformly affect fiber formation kinetics and stability for 
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different amyloidogenic proteins, rather, specific and in fact, sometimes opposite effects 
occur with different proteins.  
RESULTS 
 Urea inhibits fiber formation of Sup35NM to a larger extent than it does with 
Rnq1PFD- Previous studies have used high concentrations of urea as a standard 
component in buffers for fiber formation of Rnq1PFD (21).  Sup35NM fiber formation 
does not require urea (18,19).  Considering Sup35NM and Rnq1PFD are both the QN-
rich domains (26% for Sup35NM and 40% for Rnq1PFD is made of Q/N) of their 
respective yeast prion proteins Sup35p and Rnq1p and have a high degree of similarity in 
amino acid composition; we asked if there was a difference in the ability of a denaturant 
to suppress the aggregation propensity of either of the proteins.  Surprisingly, we noticed 
that increasing the urea concentration in Sup35NM fiber formation reactions greatly 
suppressed aggregation (Figure 1A).  Sup35NM has a lag phase of ~100 minutes in the 
absence of urea, which increases to ~300, ~400 and ~650 minutes in the presence of 0.5 
M, 1.0 M and 1.5 M urea.  Sup35NM was unable to form fibers in 2M urea in the time 
period assayed (data not shown).  Rnq1PFD fiber formation did not have an appreciable 
lag phase for fiber formation in the absence of urea.  Fibers formed in 0.5M urea with 
less than a 50 minute lag phase and in 1.0M urea this increased to ~ 100 minute lag 
phase.  Interestingly, in low concentrations of urea, the Rnq1PFD fibers tended to have 
significant amounts of noise in the Th-T fluorescence signal.  When Rnq1PFD fibers 
were formed in, however, the noise in the data was almost absent and the fiber formation 
showed an appreciable lag phase of ~ 275 minutes.   
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Figure 1: Urea inhibits rate of amyloid fiber formation in (A) Sup35NM and (B) 
Rnq1PFD. Sup35NM fiber formation was initiated by diluting (120-fold) the protein 
from 6 M GdHCl to a final concentration of 2.5µM in the reaction and Rnq1PFD fiber 
formation was initiated by diluting (75 fold) the protein from 7 M GdHCl to a final 
concentration of 4µM in the reaction.  Fiber formation was assayed by measuring 
Thioflavin-T fluorescence present in 100-fold excess. 
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Since Rnq1PFD fiber formation showed an appreciable lag phase with little noise 
in Th-T fluorescence assays only in the presence of 2 M urea, we performed experiments 
to test the effects of other solvent conditions on Rnq1PFD fiber formation in the presence 
of 2M urea. Since Sup35NM formed fibers with an appreciable lag phase and with little 
noise in the absence of urea, we did not add urea to test the effect of other solvent 
conditions for Sup35NM. 
Solvent conditions dramatically affect kinetics of amyloid fiber formation- We 
then asked what effect changing solvent conditions had on the kinetics of amyloid fiber 
formation.  To this end, we analyzed increasing concentrations of salt, divalent cations, 
osmotic stress agents and molecular crowding agents for an effect on the lag phase as a 
measure of the propensity to form amyloid fibers.   
We noted that the lag phase for fiber formation of Sup35NM did not change with 
increasing concentrations of NaCl and the lag phase was ~180 minutes for all 
concentrations of NaCl added to the reaction (Figure 2A).  For Rnq1PFD fiber formation, 
however, increasing the concentration of NaCl greatly decreased the lag phase and 
enhanced fiber formation.  The lag phase for Rnq1PFD fiber formation in reactions 
containing 100mM NaCl was ~400 minutes (Figure 3A).  This decreased to ~ 350 and 
~300 minutes when the concentration of NaCl was increased incrementally to 250mM 
and 500mM respectively.  Further increase in the concentration of NaCl to 750mM and 
1000mM decreased the lag phase to ~275 and ~200 minutes respectively (Figure 3A).   
Increasing the concentration of divalent cations (MgCl2) resulted in an increase in 
the lag phase for both Sup35NM and Rnq1PFD, suggesting partial inhibition of fiber 
formation.  Sup35NM fiber formation lag phase increased from ~ 200 to ~250 minutes, 
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Figure 2. Sup35NM fiber formation kinetics is differentially affected by different solvent 
conditions (A) Sodium Chloride (NaCl), (B) Magnesium Chloride (MgCl2) (C) Sorbitol 
(D) Glycerol and (E) PEG.  Sup35NM fiber formation was performed at 2.5µM 
concentration (120 fold dilution from denaturant) in followed by Th-T fluorescence (50 
fold excess).  These experiments have been done twice and representative graphs are 
shown.  
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Figure 3. Rnq1PFD fiber formation kinetics is differentially affect with different solvent 
conditions (A) Sodium Chloride (NaCl), (B) Magnesium Chloride (MgCl2) (C) Sorbitol 
(D) Glycerol and (E) PEG.  Rnq1PFD fiber formation was performed at 4 µM 
concentration (75-fold dilution from denaturant) and followed by Th-T fluorescence (50 
fold excess).  These experiments have been done twice and representative graphs are 
shown. 
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with an increase in concentration of MgCl2 to 100mM and 250mM.  The lag phase 
further increased to ~350, ~400 and ~525 minutes at concentrations of 500mM, 750mM 
and 1M  MgCl2 respectively (Figure 2B).  We saw a similar effect of increased lag phase 
for Rnq1PFD fiber formation from ~300 minutes in 100mM MgCl2 to ~400 and ~500 
minutes with 750mM and 1000mM MgCl2 (Figure 3B). 
An increase in the concentration of sorbitol did not affect lag phase of fiber 
formation for both Sup35NM and Rnq1PFD proteins.  Sup35NM had a lag phase of ~170 
minutes in the presence of all the concentrations of sorbitol used (100mM – 1M) (Figure 
2C).  For Rnq1PFD, the lag phase of fiber formation varied subtly from 480 minutes to 
520 minutes (Figure 3C) with no correlation to concentration of sorbitol. 
We next tested the ability of the two proteins to aggregate in the presence of 
glycerol.  We used glycerol to assay the effect of solvent viscosity on amyloid fiber 
formation.  We saw that with both Sup35NM and Rnq1PFD increasing the solvent 
viscosity increased the lag phase of fiber formation.  The Sup35NM lag phase was ~150 
minutes at 1% glycerol and 5% glycerol.  It increased to ~200, ~250 and ~320 minutes at 
10%, 15% and 25% glycerol concentrations (Figure 2D) respectively.  With Rnq1PFD, 
the lag phase was ~400 minutes with 1% glycerol.  It increased to ~670 minutes with 5% 
and 10% glycerol.  The lag phase was further increased to ~730 minutes with 15% 
glycerol (Figure 3D).  
Finally, we tested the effect of molecular crowding on amyloid fiber formation 
with Sup35NM and Rnq1PFD.  With both the proteins we observed that, PEG, which 
was used as the molecular crowding agent, decreased the lag phase, presumably 
enhancing the ability of the protein to aggregate.  We noted that with Sup35NM the lag 
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phase was ~120 minutes with 1% PEG.  It decreased to ~75 minutes with 5% PEG and to 
~50 minutes with 10%, 15% and 20% PEG (Figure 2E).  With Rnq1PFD, the length of 
the lag phase was ~475 minutes in 1% PEG.  It decreased to 350 minutes with 5% PEG. 
This further decreased to ~300 minutes with 10%, 15% and 20% PEG.   
 Sup35NM and Rnq1PFD fibers formed in various solvent conditions have 
different thermostabilities- The differences in the thermal stabilities of amyloid fibers can 
be used as an indicator of differences in the structure of the fibers.  We identified specific 
concentrations of the various conditions used previously for kinetic characterization to 
determine whether these were changes in the thermostability of the fibers formed in those 
conditions.  We chose concentrations in each condition at which there was a significant 
change in the kinetics as compared to the control fiber formation buffers (FFB or FFB + 
2 M urea) for each protein.  Fibers of Sup35NM and Rnq1PFD were formed in the 
chosen solvent conditions.  Subsequently, the fibers were then incubated in the presence 
of 2% SDS and individual samples were treated to increasing temperatures from 25○C to 
95○C (in 10○C intervals).  The treated samples were then assayed by SDS-PAGE, western 
blot and the protein bands were quantified.  There were significant differences in the 
thermostabilities of the fibers formed in the different conditions for Sup35NM (Figure 
4A) and subtle differences for Rnq1PFD (Figure 4B). 
We noted that the variation in stability of Sup35NM was much greater when 
compared to Rnq1PFD (Figure 4).  In fact, Sup35NM fibers formed in 1.0M urea were 
completely thermolabile and did not show any resistance to thermal denaturation (Figure 
4A).  The addition of sodium chloride, PEG, sorbitol and magnesium chloride all 
increased the stability of fibers formed with Sup35NM (Figure 4A).  With Rnq1PFD  
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Figure 4. Thermostability of amyloid fibers formed by (A) Sup35NM and (B) Rnq1PFD 
varies significantly when they are assembled in different solvent conditions.  Fibers were 
formed end over end rotation for 3 days at 2.5 µM concentration for Sup35NM and 4µM 
concentration for Rnq1PFD.  This experiment has been done once and needs to be 
repeated for Sup35NM and has been done two times for Rnq1PFD.  
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fibers, we also saw an increase in stability of the fibers with the addition of sodium 
chloride, sorbitol and PEG (Figure 4B).  Surprisingly, we noted that in sharp contrast to 
Sup35NM, increasing the concentration of urea in the fiber formation buffer actually 
enhanced the stability of Rnq1PFD fibers.  Fibers formed in 0.5 M urea had a t1/2~60○C 
as compared to fibers formed in 1M urea, which had a t1/2~70○C.  Fibers of Sup35NM 
and Rnq1PFD formed in NaCl however increased the stability of the fibers to the greatest 
degree amongst all tested conditions for both polypeptides.  Sup35NM fibers formed in 
1M NaCl had a t1/2~73○C and Rnq1PFD fibers in 1M NaCl had a t1/2~76○C.  Although 
sorbitol did not affect the lag phase of fiber formation for either Sup35NM or Rnq1PFD, 
fibers formed in 500mM sorbitol had significantly enhanced the stabilities of the fibers.   
DISCUSSION 
 The yeast prion proteins, Sup35NM and Rnq1PFD, have both been shown to 
readily form amyloid fibers at physiological pH.  Sup35NM forms ordered amyloid fibers 
in a potassium phosphate buffer, pH 7.4, with 150 mM sodium chloride when diluted 
from a denatured state.  With Rnq1PFD, however, the presence of urea in the buffer is 
desired to obtain a majority of ordered amyloid fibers.  We suggest that Rnq1PFD forms 
many non-specific aggregates in the absence of urea and that the denaturant either 
prevents the formation of the non-specific aggregates or renders them unstable, thereby 
allowing for more protein to participate in ordered amyloid fiber formation.  Non-specific 
aggregation of Rnq1PFD in the absence of urea may be due to an increase in the inherent 
ability of the protein to aggregate as compared to Sup35NM.  The lower aggregation 
propensity of Sup35NM is also reflected in the inability of this protein to form amyloid 
fibers in the presence of high concentrations of denaturant.   
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 Previous work has shown the prevalence of a high degree of structural 
polymorphism of various amyloidogenic proteins both at different and within the same 
solvent conditions (22,23).  In this study, we have utilized the two polypeptides, 
Sup35NM and Rnq1PFD, with differential propensities to aggregate to decipher the 
interplay between solvent conditions, kinetics, stability, and fibrillar morphology.  We 
modulated the rate of fiber formation of the proteins by changing solvent conditions with 
an expectation that this would change the morphology of the fibers.  We assayed changes 
to the structure of the amyloid fibers using a thermal stability assay.  We will further 
characterize differences in the morphology of the fibers using AFM and TEM techniques, 
Th-T fluorescence, FTIR and CD spectra.  
 The relationship between amyloid fiber formation and the various solvent 
conditions is complex.  Surprisingly, we observed that for certain conditions, the 
Sup35NM and Rnq1PFD kinetics behaved differently and for other conditions they 
behaved similarly.  For example, sorbitol did not have an effect on lag phase of fiber 
formation for either protein, but sodium chloride increased the lag phase of fiber 
formation for Rnq1PFD and had no effect on the lag phase for Sup35NM fiber formation.  
Therefore, we suggest that the interaction of the amyloid fiber forming peptide and the 
solvent is sequence-dependent.  This interaction may influence intra- and inter-molecular 
interactions of the monomeric subunits of the proteins that form amyloid fibers.  The 
pathway that a protein follows to convert from a monomer to an amyloid fiber may also 
be influenced by the solvent conditions.  These and other effects that the solvent 
conditions have on fiber formation may be avenues that a protein utilizes to generate 
polymorphisms in the resulting amyloid fiber.  
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Our data show that there is no definitive correlation between the length of lag 
phase of fiber formation and fiber stability.  For example, 10% PEG decreased the length 
of lag phase when compared to control fiber formation conditions and increased the 
stability of these fibers for both Sup35NM and Rnq1PFD.  In contrast, 100mM MgCl2 
increased the length of lag phase, but this condition also increased the stability of the 
fibers for both proteins. It is yet to be determined if there is a correlation between length 
of lag phase and stability of fibers at different concentrations of the variable component 
in a specific solvent condition. 
Previous work has explored the effect of salts on the aggregation propensity of 
Alzheimer’s Aβ (1-40), α-synuclein, glucagon, insulin and β2-microglobulin (15,24-26).  
Aβ(1-40) showed a trend where aggregation became more favorable with the increasing 
salt concentrations of both NaCl and MgCl2 (25).  MgCl2 enhanced fiber formation for 
both Rnq1PFD and Sup35NM.  However, NaCl enhanced fiber formation only for 
Rnq1PFD and had no effect on Sup35NM.  The effect of salts on aggregation may be due 
to either peptide-salt interactions or via changes in the water structure (surface tension).  
Considering we observed a mixed effect on aggregation with the different salts, we 
suggest that the kinetics of fiber formation is depended on a combination of both effects 
of salts in a solvent.  
Sorbitol has been shown previously to act as a stabilizing osmolyte and 
specifically counteract the effect of urea on fiber formation of immunoglobulin light 
chain (27).  The mechanism of the stabilizing osmolytes is thought to be non-specific.  
With Sup35NM and Rnq1PFD, we did not observe stabilizing effects by sorbitol.  This 
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may be presumably due to the fact that both these proteins have already been denatured 
and therefore are not capable of being stabilized by the osmolytes.   
Glycerol which is another solvent condition, tested, that we noted that it inhibited 
fiber formation for both Sup35NM and Rnq1PFD.  However, previously, it has been 
shown to act as an hydrating agent and enhance the aggregation of Aβ (28) as well as to 
inhibit the conversion of PrPC to PrPSc (29,30) by acting as a chemical chaperone and 
stabilizing the native conformation.  We propose that in Sup35NM and Rnq1PFD, 
glycerol is acting as a chemical chaperone to inhibit fiber formation.  We suggest that the 
concentrations of glycerol that have been used in the experiments may not be sufficient to 
cause the inhibition by increasing the viscosity based on the experiments conducted with  
α-synuclein (31).  However it is theoretically possible that the effect of viscosity is 
greater for Sup35NM and Rnq1PFD fiber assembly than is for α-synuclein. 
PEG is a polymer commonly used to simulate molecular crowding (32). Previous 
studies have shown PEG to accelerate amyloid fiber formation of α-synuclein and 
apolipoprotein C-II (31,32).  As proposed previously, we suggest that the acceleration in 
fiber formation observed for Sup35NM and Rnq1PFD is due to excluded volume effects 
and decreased solubility of the protein (31).  
 An ongoing experiment that may provide very interesting results is in regard to 
the influence that the various conditions may have on the the fibers in inducing yeast 
prion variants in vivo.  To this end, we have transformed the fibers formed in the 
different conditions into [prion-] yeast cells.  We will determine the prion variants of 
[PSI+] and [RNQ+] that the fibers induce and further investigate their in vivo and in vitro 
properties.  We will then attempt to draw correlations between the solvent conditions, 
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biochemical properties of the fibers, and in vivo properties of the prion variants.  The 
ability to study the properties of the amyloid fibers in vitro and then investigate their in 
vivo aggregation and resultant phenotype, is a powerful tool to investigate novel features 
of protein aggregation.  Further, the in vivo studies will help us correlate the in vitro fiber 
properties to their biological relevance in a cellular context.    
 We propose that these data and ongoing and future experiments will help us 
determine correlations between different solvent conditions and their influence on 
amyloid fiber formation and polymorphism.  This information may provide clues toward 
understanding the cell and tissue specificity of protein aggregation diseases.  
Additionally, understanding the underlying principles of amyloid polymorphisms may 
help elucidate the mechanisms of strains in “protein-only” diseases.  Finally, 
differentially stable amyloid fibers may provide novel avenues to develop tailored 
polymers for use as materials.   
EXPERIMENTAL PROCEDURES 
Protein expression and purification of recombinant proteins –  Sup35NM was purified as 
reported previously (33).   
 The pHis10-Rnq1PD (amino acids 132-405) construct (21) was transformed into 
Escherichia coli BL21(DE3) cells.  Resultant transformants were scraped to inoculate 
large cultures in CircleGrow media and the cells were grown to an OD600~0.6.  The 
expression of Rnq1PFD was induced with 1 mM IPTG for 6 hrs.  The cells were 
harvested and incubated with agitation at room temperature for one hour in 20 mM Tris-
HCl, 8 M Urea (Buffer A, pH 8).  The cells were then further lysed by sonication.  The 
lysate was cleared by spinning at 10,000 x g for 30 minutes.  The supernatant was 
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incubated with Ni2+-Sepharose beads for two hours.  Subsequently, the beads were 
packed in a column and washed with 25 column volumes (CV) Buffer A, pH 8.  The 
beads were then washed successively with four CV each of Buffer A, pH 6.3 and Buffer 
A, pH 5.9, before eluting with Buffer A, pH 4.5.  Rnq1p in the eluted fractions was 
verified for purity by SDS-PAGE and coomassie staining.  The fractions containing the 
protein were filtered through a 100kD molecular weight cut off column (Amicon) and 
stored in methanol at -80○C.  
Amyloid fiber formation- Kinetic assays of fiber formation were done in a SpectraMax 
M2e flourimeter microplate reader.  Sup35NM monomers were diluted 120-fold from 6 
M guanidine hydrochloride to a concentration of 2.5 µM in FFB buffer (150 mM NaCl, 5 
mM KPO4) and Rnq1PFD monomers were diluted 75-fold from 7 M guanidine 
hydrochloride to a concentration of 4 µM in FFB + 2M Urea buffer (150 mM NaCl, 5 
mM KPO4, 2 M Urea, pH 7.4) with 50-fold molar excess Thioflavin-T to initiate fiber 
formation in the presence of glass beads for agitation.  The change in Thioflavin-T 
fluorescence over time was measured using an excitation wavelength of 450 nm and 
emission wavelength of 481 nm.  The plate was agitated each minute prior to reading for 
ten seconds.  
For the various other buffer conditions, except when concentration of urea itself was 
varied, the other agents were added to the mentioned to the final concentration to FFB 
buffer and FFB + 2M urea buffer for Sup35NM and Rnq1PFD respectively.  
Thermostability assay- Pre-formed fibers were treated with 2% SDS for five minutes at 
different temperatures (gradient from 25○C to 95○C, with 10○C increments).  The treated 
samples were analyzed by SDS-PAGE and western blot using an anti-Rnq1p or anti-
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Sup35p antibodies.  The bands were quantified using ImageJ software and values were 
normalized to the 95○C band.  Results were plotted using Origin 6.1 statistical software. 
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6.1 Sup35-PrP chimeras future directions 
Summary 
 The reason for the onset of a subset of the inherited forms of prion disease is 
suggested to be due to the ability of the mutation in the gene to destabilize the native 
conformation of the protein and presumably enhance its ability to induce the prion state 
(1).  In the case of repeat expansion mutations in prion disease, previous studies have 
observed a correlation between the length of expansion and age of onset (2).  
Additionally, previous work done in our lab demonstrated that the repeat-expanded 
fusion protein of Sup35p and PrP maintain a stronger variant of the [PSI+] prion in yeast 
cells (3).  Therefore, we hypothesized that the repeat expansions may play a role in 
increasing the inherent capacity of the protein to aggregate.  Purified recombinant 
chimeric proteins of Sup35-PrP did in fact show an ability to aggregate in vitro, however, 
the chimeras did not show a correlative increase in the stabilities of the aggregated 
conformation.   
Determine the amyloid core of SP14NM variants 
Another interesting observation we made with a specific repeat expansion of 
Sup35-PrP fusion which contained 14 octapeptide repeats was the ability of this fusion to 
switch between prion variants (3).  We observed that in vivo, the SP14 prion was capable 
of converting from a strong variant to a weak variant and back at a high frequency.  This 
ability to switch between prion variants was not observed for [PSI+] formed from the 
wild type Sup35p or the shorter repeat expansions.  In Chapter 2, I demonstrate that 
SP14NM can form amyloid fibers in vitro and, when transformed into yeast cells, they 
induce the prion state.   
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Preliminary experiments have shown that when SP14NM fibers are formed at 
different temperatures and transformed into yeast they produce different variants of the 
[PSI+] in vivo.  The physical basis for prion variants has been proposed based on the 
ability of Sup35NM fibers formed at different temperatures to induce distinct variants in 
vivo (4,5).  However, in contrast to the variants maintained by SP14NM, these variants 
are stable and do not switch between strong and weak variants with a high frequency.  I 
hypothesize that the ability of the SP14 chimeric protein based variants are able to allow 
for the high frequency switch between variants is based on the conformation that the 
SP14 monomers adopt when they aggregate.  I speculate that the structural difference 
between two strains formed from the SP14 protein is very little when compared to the 
structural differences between two strains based on Sup35p.  
In order to address this hypothesis, I made reagents that may prove useful in 
investigating the structural variation between the strains of SP14NM fibers formed at 
different temperatures.  I took advantage of the fact that SP14NM does not contain any 
endogenous cysteine residues and introduced single cysteine mutants that spanned the 
SP14NM protein fragment. I made eight cysteine substitution mutations in SP14NM to 
interrogate the orientation of different regions of the protein based on fluorescence 
labeling techniques used previously for Sup35NM (6).  I suggest that future experiments 
be focused on labeling the recombinant cysteine mutants of SP14NM with fluorophors 
such as pyrene, acrylodan and alexa fluor-488 (or others) in order to determine the 
environment of the amino acid labeled in SP14NM.  Both pyrene and acrylodan are 
sensitive to the solution environment and produce a shift in fluorescence based on their 
surrounding polar or non-polar environment.  This property will be useful in identifying 
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regions of the protein that are exposed or buried to the solvent.  Additionally, pyrene also 
has the ability to form excimers with neighboring pyrene molecules.  This property of 
pyrene will be useful to determine inter-molecular sites of interactions by measuring 
excimer formation of two different labeled cysteine mutants mixed together.   
Elucidating the structure of SP14NM in amyloid fibers created at different 
temperatures may provide a means to understand mechanisms behind the phenotypic 
variability observed in neurodegenerative diseases.  Furthermore, it may provide clues 
toward elucidating the reason why SP14NM is capable of forming amyloid fibers at a 
much greater efficiency when compared to the wild type Sup35NM and non-repeat-
expanded SP5NM proteins. 
We also observed, as mentioned in Chapter 2, that the morphology of the amyloid 
fibers was significantly different for the different chimeras.  We observed that SP5NM 
(chimera with wild type number of repeats) fibers were ordered and did not form a 
meshwork or clumps of fibers. The repeat expanded chimeras, SP8NM, SP11NM and 
SP14NM however all formed a meshwork or clumps of fibers.  It is important to note that 
only the repeat-expanded chimeras are associated with inherited prion disease and cause 
pathology.  Understanding conformational differences between the wild type chimera and 
the repeat-expanded chimera using techniques proposed in this chapter or using H/D 
exchange NMR techniques used for Sup35NM previously (7) may prove important in 
understanding conformational differences between aggregates that are associated with 
pathology and those that are not.  This is especially biologically significant because 
protein aggregation has been shown to be present in the absence of disease, suggesting 
that there may be certain forms of aggregates that are not pathological (8).   
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 Another independent reason for the phenotypic variability seen in [SP14+] cells 
may be due the prion state actually being lost and then SP14 protein aggregating de novo 
to form a novel variant. It is plausible that in yeast cells that the de novo aggregation of 
the already aggregation-prone SP14 protein may be facilitated by [RNQ+].  The 
interaction of the aggregated Rnq1p with SP14 may allow for phenotypic variability.  
This interaction may prove to be a useful model in elucidating the nature of the 
interaction between amylodogenic proteins in disease to cause phenotypic variability in 
humans.  Recent reports have provided evidence to suggest that the aggregation of one 
protein may template the aggregation of a different protein in various diseases and 
disease models (9,10).  One avenue for disease onset and phenotypic variability may be 
the cross-talk between two aggregation prone proteins and Rnq1p and SP14/ SP14NM 
may provide a useful model to elucidate these mechanisms both in vivo and in vitro. 
Conclusions  
The Sup35-PrP chimera with various disease-associated repeat expansion 
substitutions provides a genetically tractable and biochemical means to assay multiple 
aspects of protein aggregation and amyloid fiber formation.  The ability to understand the 
structural properties of the disease-associated mutants and then transform those 
aggregates into cells provides a powerful tool to decipher the relationship between 
structural changes and phenotype or disease.  The above experiments proposed are aimed 
at understanding the molecular basis of variation in phenotypes and co-aggregation of 
proteins in various progressive and fatal diseases in humans. 
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6.2 Structure of Rnq1PFD in prion variants of [RNQ+] 
Summary 
 One of the most intriguing properties of proteins that form amyloid fibers is their 
ability to access multiple stable conformations.  These conformations are also capable of 
faithfully templating their structure onto unconverted monomeric forms of the protein.  
Yeast prions can also propagate with multiple conformations.  A physical basis for the 
existence of yeast prion strains has been proposed based solely on the experiments done 
with Sup35NM (5).  In chapter 3, I have done work toward identifying common and 
distinct features that are shared between [RNQ+] and [PSI+] prion variants.  The 
molecular structure of the prion variants generated by forming amyloid fibers with 
Sup35NM has been studied in detail using multiple approaches (6,7,11).  However, not 
much is known about the amyloid structure of Rnq1PFD or its variants. 
Determine the amyloid core of Rnq1PFD variants 
 In order to elucidate the amyloid core of the Rnq1PFD variants, I have generated 
15 cysteine mutants that span the sequence of this protein.  Future experiments will 
include using techniques used previously (6) to determine what regions of the protein that 
are involved in forming the amyloid core as well as amino acids in Rnq1PFD that are 
involved in inter-molecular interactions.  Further structural characterization of the 
variants could include 3D fiber topology determination using AFM and spectroscopic 
methods such as FTIR and EPR to determine secondary structure content differences 
(4,12). 
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Determine specific sites of interaction between Sup35NM and Rnq1PFD 
 Based on the heterologous cross-seeding model for enhanced [PSI+] induction in 
the presence of [RNQ+], the aggregates of Rnq1p template the aggregation of Sup35p 
resulting in the induction of [PSI+] (13).  Although there is significant amount of data to 
suggest an interaction between Sup35p and Rnq1p, the specific physical interaction 
between the two proteins is at best correlative (13-16).  Future experiments using 
reagents generated to determine the structural properties of Rnq1PFD as mentioned in 
this chapter along with reagents used to determine structural properties for Sup35NM by 
Krishnan and Lindquist (6) may provide a means to elucidate the specific interaction 
domains between the two protein fragments.  Experiments with different pairs of cysteine 
mutant proteins in cross-linking will provide information regarding interactions that are 
agonists and antagonists of cross-seeding.  Additionally, previous reports have suggested 
specific interactions between variants of [PSI+] and [RNQ+], with certain variants of one  
prion destabilizing the propagation of variants of another prion (17). This may occur due 
to specific templating interactions may induce specific variants and destroy other 
variants.  The cross-linking of cysteine residues between monomers of Sup35NM and 
Rnq1PFD may provide information about interactions that lead to the production of 
specific variants. 
Conclusions  
 The etiology of most cases of protein misfolding disorders is unknown and 
therefore classified as being “sporadic”.  I suggest that some of the sporadic cases may be 
caused by initial misfolding of proteins that are unrelated directly to disease pathology, 
but are indirectly involved in cross-seeding other aggregation prone proteins to cause 
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disease. Understanding the molecular and structural basis for the interaction between two 
different proteins that are known to interact in vivo may provide clues towards 
understanding the mechanisms that cause certain sporadic cases of protein misfolding 
diseases.  Additionally, cross-seeding of multiple proteins may also play a role in 
explaining the phenotypic diversity observed in some protein misfolding diseases (9).  
The experiments proposed above provide a platform where we may be able to start 
answering these very important disease mechanisms. 
Determine the interaction between Rnq1PFD and the yeast chaperone system 
  The role that molecular chaperones, specifically heat-shock proteins, play in prion 
propagation has been well studied in vivo (18,19).  Hsp104p is a chaperone in yeast that 
is required for the propagation of both [PSI+] and [RNQ+] (20,21).  Deletion of HSP104 
cures yeast cells of the prion state.  Intriguingly, over expression of Hsp104p only cures 
the [PSI+] prion and not the [RNQ+] prion (20).  Although the mechanism of the action 
of Hsp104p and other chaperones on amyloid fibers formed with Sup35NM has been 
well-studied in vitro (22,23), the reason for the differential effects of the chaperone 
system on [PSI+] and [RNQ+] has not been investigated.   
 I propose that using already established protocols in the lab to purify Hsp104p 
and the ability to make Rnq1PFD fibers will allow us to understand the mechanism of 
[RNQ+] prion propagation and the differential effects that Hsp104p has on different 
prions.  Future experiments that can be conducted include the effect that different 
concentrations of Hsp104p has on the lag phase of fiber formation and the variants of 
Rnq1PFD that are formed.  Additionally, experiments can be designed to detect the 
ability of Hsp104p to disaggregate Rnq1PFD fibers.  
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Conclusions 
 The ability of chaperones to modulate the aggregation and disaggregation of yeast 
prions provides a tantalizing avenue to explore therapeutic approaches that do the same in 
human diseases.  Hsp104 itself is not conserved in humans and therefore could be 
developed as a therapeutic agent (24).  More importantly, understanding the mechanism 
of how chaperones modulate protein aggregation will provide inspiration to develop 
synthetic agents with similar mechanism for use in either preventing the progress or 
curing protein misfolding disorders. 
 
6.3 Structural differences between infectious and non-infectious amyloid aggregates  
Summary 
 In chapter 4, we have begun to explore properties that make an amyloid fiber 
infectious versus non-infectious.  We used the deletion mutant of Rnq1PFD termed 
Rnq1PFD∆Hot that formed infectious fibers when assembled at 37○C, whereas, fibers 
formed at 25○C were not able to infect yeast cells to induce the [RNQ+] prion.  We have 
characterized the mutant biochemically (Th-T fluorescence and thermal stability assays).  
However, the variation in structure of the mutant when assembled at the two different 
temperatures remains to be determined.  
Determine the structural differences between Rnq1PFD∆Hot fibers formed at 25○C and 
37○C 
 The initial experiments to determine structural differences between the infectious 
and non-infectious variants of Rnq1PFD∆Hot involve the use of various spectroscopic 
techniques.  Fibers formed at the different temperatures can be assayed using CD spectra, 
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FTIR and EPR to determine the secondary structure.  Additionally, using AFM will allow 
the identification of morphological differences between fibers formed at the different 
temperatures that were not easily discernable using TEM.   
 The subsequent experiments should concentrate on investigating the differences 
in the structure of the protein in the fibers at a higher resolution.  The use of HD-
exchange NMR or biophysical techniques to identify the orientation of regions of the 
protein as used in the studies referenced (6,7) will provide useful information regarding 
the structural signatures that determine the infectivity of an amyloid fiber.  The 
generation of cysteine mutants that span the Rnq1PFD∆Hot region will be a critical step 
toward doing the experiments proposed above. 
 An alternative reason for the differences in the ability of the two variants to 
induce the prion in vivo may be due to differences in the effect of various chaperones on 
the amyloid fibers.  Therefore, experiments designed to elucidate the effect of Hsp104p 
and other yeast Hsps may provide critical details that help differentiate between 
infectious and non-infectious amyloid fibers.  To characterize the effect of chaperones on 
Rnq1PFD∆Hot fibers, Th-T fiber formation assays and fiber disaggregation assays can be 
conducted by treating the fibers with increasing concentrations of Hsp104p in 
combination with other yeast chaperones. 
Conclusions 
 The proposal that all protein aggregates that form amyloid fibers can be infectious 
is a currently hotly debated and investigated area of research (25-28).  Since, most 
amyloid fibers seem to undergo a “nucleated polymerization model” for fiber formation, 
it is conceivable that all of them are infectious.  However, I hypothesize that differences 
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in the rates of nucleation, aggregation and fragmentation of the fibers will determine the 
ability of an amyloid fiber to be infectious and that the specific conformation that a 
monomer acquires when it becomes part of an aggregate plays a major role in 
determining these properties.  The Rnq1PFD∆Hot protein fragment and the [RNQ+] yeast 
prion provides us with a unique model system to interrogate the differences between 
infectious and non-infectious amyloids in both in vitro and the in vivo conditions. 
 
6.4 Correlation between amyloid fiber morphology and solvent conditions  
Summary 
 The polymorphism in amyloid fiber preparations can be readily observed using 
techniques such as AFM or TEM (29-31).  Protein aggregates in disease have also shown 
morphological differences when observed by cryo-EM (32).  Various possibilities may 
cause the differences in the structure of the amyloid fibers, including differences in the 
assembly of individual amyloid fibers into bundles and variations in the inter- and intra-
molecular contacts that the monomers make during polymerization.  Environmental 
changes could play a major role in influencing the distribution in morphology of the 
fibers.  In chapter 5 of this thesis, we have used Sup35NM and Rnq1PFD to dissect the 
interaction between amyloid fiber polymorphism and solvent conditions.   
 
Morphological characterization of amyloid fibers 
 Experiments described in chapter 5 of this thesis have provided evidence to 
suggest that amyloid fibers of Sup35NM and Rnq1PFD formed in different solvent 
conditions have distinct biochemical properties.  In addition, Sup35NM and Rnq1PFD 
seem to interact differently with the solvents, suggesting that the biochemical properties 
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and morphologies of amyloid fibers may be a consequence of both protein sequence and 
environmental conditions.  The goal of this chapter is to draw correlations between 
solvent conditions, amyloid fiber morphologies and prion variant creation.  In order to 
determine the structural differences between the amyloid fibers formed in various solvent 
conditions, future experiments will use spectroscopic techniques such as CD, FTIR and 
EPR to determine secondary structure content.  Additionally, the supra-molecular 
structural differences will be determined using AFM and TEM imaging.   
 Additional experiments that correlate morphologies of amyloid fibers to the prion 
variants they induce in vivo will be done using yeast protein transformation techniques.  
It will be interesting to identify weather there are any correlations between amyloid 
morphologies, prion variants and infectivity.   
 Future directions could also include testing the tensile strength of the fibers 
formed from the different proteins in different conditions using the AFM.  The data 
obtained from these experiments could provide valuable information regarding potential 
material properties of the fibers.  Using these properties as a guide, one can envision 
developing conditions that can tailor the physical properties of fibers formed from 
various proteins to use as a source for materials.  
Conclusions 
 Understanding the basis for polymorphism in the structure of amyloid fibers and 
developing techniques to control the morphology of amyloid fibers has implications both 
in understanding phenotypic variation in disease and in developing biodegradable tailor-
made materials for various applications.  By using Sup35NM and Rnq1PFD as model 
amyloidogenic proteins, we hope to elucidate the interactions between solvent conditions 
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and amyloid fibers.  Furthermore, we anticipate identifying sequence-specific differential 
interactions between solvent conditions and amyloidogenic proteins.  These studies may 
also facilitate identification of environments risk factors for protein misfolding diseases.   
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